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Abstract
Dual energy (DE) computed tomography (CT) has the capability to influence medicine and
pre-clinical research by providing quantitative information that can detect nascent lesions,
identify perfusion restoration or inhomogeneities within tissues, and recognize the presence of
calcium deposits. A wide variety of instrumentation techniques and scan protocols have been
developed for DE CT, with a common goal of acquiring a pair of images that reports the
attenuation of a given volume to two different x-ray distributions. While DE image acquisition
has benefitted from technical advancements in CT, the contrast agents that are used are still
predominantly composed of iodinated small molecules, which first appeared in the 1970s.
Recent work has demonstrated that lanthanide-based contrast agents have optimized properties
for DE decomposition, specifically when using in vivo micro-CT scanners. By adopting
nanoparticle design strategies that were developed for disease therapeutics and diagnosis, this
thesis takes advantage of existing technical advancements in nanotechnology and polymer
science to develop a long-circulating contrast agent that can be used for in vivo micro-CT and
DE micro-CT imaging of the mouse vasculature. The contrast agents that were developed
provided a high loading of 100 mg/mL of lanthanide for intravenous injections of mice, and
introduced CT contrast enhancements of at least 245 HU. The contrast was maintained for at
least 30 minutes, and for as long as one hour, which exceeds the in vivo micro-CT scan time
requirements. Furthermore, although the synthesis techniques and in vivo scans were
demonstrated using model lanthanides such as gadolinium and erbium, they can easily be
substituted by any other lanthanide. By using a fast-filter switcher to obtain interleaved scans,
the feasibility of an in vivo DE CT technique that produces decomposed quantitative images
of soft tissue, bone and gadolinium-enhanced vessels was demonstrated, which can be used
with any pre-clinical, gantry-based micro-CT scanner. When used in combination with the
DE CT technique presented, the long-circulating lanthanide contrast agents that were
developed in this thesis have the potential to become powerful tools for pre-clinical research
on the microvasculature.

ii

Keywords
Contrast agent, micro-computed tomography, dual energy, nanoparticles, gadolinium,
lanthanides, vasculature, long circulation

iii

Summary for Lay Audience
Cardiovascular disease is studied in mouse models so that treatment and prevention methods
can be developed for humans. To study the heart and vessels, 3D images of the mouse body
can be obtained using computed tomography (CT). CT uses x-rays, and results into greyscale
3D images that represent the density of the volume being captured. For instance, low density
organs like the lungs may appear black or dark grey, and high-density tissue like bone appears
white. Since vessels have comparable densities as other soft tissues, they result in similar
greyscale values, unless a dye containing a high-density material is injected into the blood.
However, dyed vessels appear like bone in CT images and become difficult to distinguish when
they are inside or near bone. A technique called Dual Energy CT allows us to discriminate
between soft tissue, bone, and dyed vessels. Two chapters of this thesis feature the
development of a dye that can be used in living mice so that vessels can be mapped by Dual
Energy CT without the need for surgery. The physical properties of the dyes that were
developed were modeled after existing pharmaceutical drugs composed of nanoparticles within
polymers. Nanoparticles are materials sized in the nanometer range, and polymers are large
molecules with repeated subunits. The dye was composed of a type of metal called a
lanthanide, which can successfully map mouse vessels post-mortem by Dual Energy CT. A
chapter of this thesis demonstrates that the lanthanide dye – when used in combination with
Dual Energy CT – gives researchers the ability to distinguish between soft tissue, bone, and
dyed vessels in living mice. The presented Dual Energy CT technique and dye design can allow
researchers to track anatomical changes in the same mice over time, which can provide new
information and further understanding of vascular diseases.
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Chapter 1
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INTRODUCTION

Dual energy (DE) computed tomography (CT) is an imaging technique that can
differentiate materials within a given volume using a pair of CT images that were obtained
from distinct x-ray spectra.1, 2 DE imaging takes advantage of the change in a material’s
attenuation of x rays when the energy spectrum is modified.3 The capability to distinguish
between specific materials within imaging volumes is beneficial when differentiating
structures that have similar CT attenuation values. For example, the composition of renal
calculi can be identified through DE CT by using the inherent difference in x-ray
attenuation of each calculus type when the energy spectrum is varied.4 Another application
of DE CT is the identification of calcified plaques within a vessel lumen that contains a
vascular contrast agent. In addition to tissue separation, DE CT can also be used to quantify
the concentration of the contrast element within a volume.1 This would enable the detection
of revascularization within injured tissues, or the identification of hypoperfusion in tissues.
Regardless of the reason for DE CT, the material decomposition results can be used to
understand pathologies in more detail than the information acquired from conventional
single energy CT, so that further tissue characterization or appropriate disease treatment
may proceed.
Recent developments in DE CT have made the acquisition of DE images feasible on
clinical scanners and in pre-clinical research. Advancements in clinical DE CT imaging
include the development of dual source-dual detector systems,5 dual layer detectors,6 and
rapid kVp switching,7 which enables acquisition of DE images in under a minute. In preclinical DE CT using micro-CT scanners, spectral tuning can be achieved using filters that
can shift the average photon energy to acquire the desired spectra,8 providing DE images
in 10 minutes. Both clinical and pre-clinical cases require the use of a contrast agent, and
these are predominantly based on iodine. Iodinated agents have been used in x-ray imaging
since the 1970s, as they were initially developed for use in radiography.9, 10 While there are
some benefits to using iodine, more effective DE decomposition can be achieved using
higher Z elements.11 Despite developments in the technical aspects of DE CT, there has

2

been a lag in the parallel development of novel contrast agents for DE CT. This thesis
describes the development of a new lanthanide-based contrast agent for use in micro-CT
studies of mouse models. Using one of the developed contrast agents, an in vivo DE CT
technique that produces quantitative images of decomposed soft tissue, bone, and
gadolinium volumes is demonstrated, which can be used with any pre-clinical, gantrybased micro-CT scanner. To introduce the topic, I will summarize the principles behind
DE CT and the pharmacokinetics of contrast agents.

1.1 X-ray Spectra in DE CT
The separation between the low- and high-energy spectrum (i.e. spectral separation) is
important when using widely available iodinated agents because it maximizes the
difference between the low attenuation of the iodine-containing tissues in the high-energy
image, and high attenuation in the low energy image due to the K-edge, which will be
discussed in the next section. Ideally, DE CT would utilize photons of two energies - one
just below and one just above the K-edge of the contrast agent being used.12 However,
available x-ray sources (x-ray tubes) generate polychromatic x-ray spectra composed of a
continuous spectrum of bremsstrahlung radiation superimposed with characteristic lines of
the tungsten material of the anode. Hence there are two x-ray spectra rather than two
distinct photon energies. The maximum energy of the photons is defined by the peak
voltage (kVp), while the mean energies are significantly lower.

1.1.1

Clinical X-ray Spectra

Typically, in clinical settings, filtered 80 and 140 kVp x-rays are used because they are
readily available, and provide optimized spectral separation with standard x-ray tubes.13
Example normalized spectra of 80 and 140 kVp photons from a standard tungsten tube
(filtered by 0.2 mm of copper and 2.5 mm of aluminum) are shown in Figure 1.1A. There
is a significant overlap between the energy distributions of the 80 and 140 kVp photons –
reflected by their respective mean energies of 51 and 68 keV – necessitating additional
filtration. A filter is applied to remove low energy photons from the high energy spectra
(i.e. harden the beam), thereby decreasing the overlap between the pair of beams. For
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example, filtering the 140 kVp photons with 0.4 mm of tin hardens the beam, resulting in
a mean energy of 89 keV (Figure 1.1a).
The mean energy is further increased by the patient volume. For example, placing a
cylinder of soft tissue with a diameter of 30 cm in the field of the x rays hardens the 80 kVp,
140 kVp and tin-filtered 140 kVp beams, such that the exiting x-rays have higher mean
energies (60, 87, and 98 keV, respectively in Figure 1.1b). While there is spectral
separation between 80 and 140 kVp beams post beam hardening, the overlap worsens with
increasing patient size. Spectra at energies higher than 140 kVp are generally not available
with today’s tubes but could offer better spectral separation.13

Figure 1.1 Standard energy distributions of photons used by clinical DE CT protocols.
a) Energy distributions of incident 80 and 140 kVp photons filtered inherently with 0.2 mm
copper and 2.5 mm aluminum, and 140 kVp photons filtered inherently and an additional
0.4 mm of tin. b) Once attenuated by 30 cm of soft tissue, the energy distribution shifts to
the right as the beam is hardened. Spectra were simulated using SPEKTR 3.0.14, 15

1.1.2

DE Micro-CT Spectra

While DE imaging using clinical CT scanners and micro-CT scanners share common x-ray
spectra principles, micro-CTs have some limitations. Micro-CT scanners operate in a more
limited energy domain (i.e. 30-90 kVp being common, with some scanners using tubes
capable of generating 120 kVp spectra) than clinical CTs (i.e. 30-140 kVp). This limitation
makes the use of filters vital in obtaining ample spectral separation between the two
spectra’s mean energies.16 DE micro-CT commonly uses 40 and 80 kVp photons,17 with
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SPEKTR 3.0-calculated mean energies of 15 and 28 keV, respectively.14, 15 Normalized
energy distributions of incident DE micro-CT photons are shown in Figure 1.2a for 40 and
80 kVp photons filtered with 0.25 mm of beryllium (inherent), and 80 kVp photons filtered
with an addition 0.1 mm of copper. Filtering 80 kVp photons with 0.1 mm of copper
reduces overlap between the energy distributions and shifts the mean energy from 28 to
44 keV in the high-energy spectrum. When a cylinder composed of 30 mm of soft tissue is
placed in the field of the x-rays to mimic a commonly scanned mouse, higher mean energies
of 28 and 42 keV are observed for the inherently-filtered 40 and 80 kVp photons, while the
mean energy increases from 44 to only 48 keV for the copper-filtered 80 kVp photons
(Figure 1.2b). While material decomposition is feasible with DE images acquired using 40
and 80 kVp photons, these require sequential scans where the low-energy images are
acquired separately from high-energy energy scans. Most micro-CTs are not yet capable
of simultaneous or near-simultaneous frame acquisitions. So far, the best means to
obtaining frames almost simultaneously at each energy is by using an external fast-filter
switcher, while the peak energy is kept constant throughout the micro-CT scan.

Figure 1.2 Standard energy distributions of photons used by pre-clinical DE micro-CT
protocols. a) Incident 40 and 80 kVp photons filtered inherently with 0.25 mm beryllium,
and 140 kVp photons filtered with additional 0.4 mm of tin. b) Once attenuated by 3 cm of
soft tissue, the energy distribution shifts to the right as the beam is hardened.
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Tissue and Contrast Material Attenuation

1.2

To allow tissue differentiation in CT, there must be a contrast between the linear
attenuations of the tissue of interest and its surroundings. CT number (𝐶) is measured in
Hounsfield units (HU), and is calculated using the linear attenuation coefficient (µ) of
specific tissues to x-rays as follows:
𝐶=

µ𝑡𝑖𝑠𝑠𝑢𝑒 −µ𝑤𝑎𝑡𝑒𝑟
µ𝑤𝑎𝑡𝑒𝑟 −µ𝑎𝑖𝑟

× 1000

(1)

Water and air are assigned C of 0 HU and -1000 HU, respectively, by convention. The
linear attenuation coefficient is the fraction of photons that is attenuated by a given
thickness of material. For the energy range used in CT imaging, this property is the sum of
coefficients attributed to the Compton effect (𝜎), coherent scatter (𝜀), and the photoelectric
effect (𝜏).18, 19 By dividing the linear attenuation coefficient (µ) by the density of the
attenuating material (𝜌), the total mass attenuation coefficient can be calculated
(Figure 1.3), along with the contributions due to each event.
µ
𝜌

𝜎

𝜀

𝜏

𝜌

𝜌

𝜌

= + +

(2)
𝜏

The mass attenuation due to the photoelectric effect, given by 𝜌 , is strongly dependent on
the atomic number (𝑍) of the material as well as the energy of the incident photons given
by ℎ𝜈,20 where ℎ is Planck’s constant and 𝜈 is the photon’s frequency (Equation 3).
𝜏

𝑍

∝ (ℎ𝜈)
𝜌

3

(3)

Since tissues are composed of compounds rather than single elements, an effective atomic
number (𝑍𝑒𝑓𝑓 ) replaces Z in Equation 3, which is defined as follows (Equation 4).
7
2

7

𝑍𝑒𝑓𝑓 = √∑𝑖(𝑎𝑖 𝑍𝑖 )2

(4)

Since the photoelectric effect strongly increases with atomic number, most tissues in the
body, composed mainly of hydrogen (𝑍 = 1), carbon (𝑍 = 6) and oxygen (𝑍 = 8), have a
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weak photoelectric effect (𝑍𝑒𝑓𝑓 = 7.5). Some atoms in the body, such as calcium (𝑍 = 20)
in bone, have higher atomic numbers, so combined with other bone elements produce 𝑍𝑒𝑓𝑓
values between 11.6 and 13.8 and have higher photoelectric effect, while soft tissues have
lower 𝑍𝑒𝑓𝑓 (7.5). Various soft tissues have only slightly different values from each other.
Contrast agents are required to temporarily increase the 𝑍𝑒𝑓𝑓 of the soft tissue it localizes
in during micro-CT scanning – hence increasing contrast – and allows its differentiation
from other soft tissues.
Currently available CT contrast agents are predominantly based on iodine, (𝑍 = 53),21
which was adapted from traditional radiography where the energies are lower. In addition
to its high 𝑍, iodine has a special property known as the K-edge at 33.2 keV. The K-edge
is the energy required to liberate an electron from the innermost shell (i.e. K-shell) of an
atom (Figure 1.3). Since incoming photons have sufficient energies to liberate a K-shell
electron, a sudden increase in attenuation occurs at the K-edge. The K-edge of iodine
occurs near the low energy region of the CT spectra, which in addition to its higher 𝑍 than
soft tissue alone, enhances contrast when the incident photons have energies just above
33.2 keV. Hence, by obtaining a pair of images at 80 and 140 kVp, the attenuation
information in the presence of an iodinated contrast agent can be used to decompose a
volume image into bone, soft tissue only, and iodine-containing soft tissue. This
decomposition can be achieved because bone and soft tissue have similar attenuation
properties at both energies, while iodine has higher attenuation in the low energy image
than in the high energy image, which reflects the attenuation trends in Figure 1.3a.
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Figure 1.3 Linear attenuation coefficients of a) soft tissue, cortical bone and iodine, and
b) contrast elements as a function of energy. In clinical DE CT, attenuation stays the same
for soft tissue and cortical bone, while iodine has lower attenuation with increased energy.
Alternatively, a pair of images can be obtained by using photons with energies that are just
below and just above the K-edge. When iodinated agents with a K-edge of 33.2 keV are
used, the image volume can then be decomposed into tissue components by using a priori
information that bone and soft tissue have decreasing attenuation properties, while iodine
has higher attenuation in the high energy image than in the low energy image. This
technique takes greater advantage of the K-edge property since the contrast element
demonstrates an opposite attenuation trend as endogenous materials in the body. However,
it is difficult to obtain photons below the K-edge of iodine in the clinical setting, as most
photons with energies below 33.2 keV are absorbed by the patient volume, contributing
only to radiation dose, and not image contrast. An alternative method to obtain mean
energies below and above the K-edge is to use elements with higher K-edges than iodine.
Figure 1.3b shows the linear attenuation coefficients of high-density elements that have
higher Z, and thus have more optimized K-edge energies for DE CT compared to iodine.
Reported work on the use of other elements as contrast materials in DE CT is discussed in
the contrast media section of this review. The selection of contrast material should be
considered upon evaluating the technical capabilities of existing dual energy scanners, and
in particular their spectral separation methods.
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1.3
1.3.1
1.3.1.1

Technical Approaches to DE CT imaging
Acquisition of DE CT Images
Acquisition in Clinical CTs

The simplest method of acquiring DE CT images is through sequential imaging, where a
separate rotation of the source and detector is required per energy. This method of acquiring
DE images would be accessible to current installations of scanners, as the only requirement
would be an image registration method between the pair of scans and the use of filters
(i.e. metal foils mounted at the x-ray tube port). In clinical scanners, it also requires
additional table movement per energy. Hence, sequential scans are more susceptible to
subject movement in between energies. Although clinical scans can be acquired in under a
minute, contrast agent localization can vary in between scans. For example, a blood pool
contrast agents may preferentially localize in the vasculature during the first scan, while it
may have increased concentration in the kidneys in the second scan.22, 23
Technical developments in CT have made simultaneous and near-simultaneous acquisition
of DE images in clinical imaging feasible. Dual source-dual detector systems that are 90º
apart within a single bore have been developed by Siemens with the SOMATOM
Definition Drive, Flash and Force.5 Rapid kVp switching can be achieved with the GE Gsi
Xstream, where a cycle time as fast as 0.25 ms per kVp per angle is achievable.7 Dual layer
detectors are also available in Philips scanners with spectral detector computed
tomography, where the first layer of detectors absorbs low energy photons and the second
layer absorbs high energy photons.6 As Petersilka and co-authors have reported, while there
is an angular offset between both spiral paths for dual source systems,24 the advantage in
acquiring DE projections simultaneously lies in the fact that the volume is in the same state
in low and high energy images. This approach minimizes image artifacts related to patient
movement. Simultaneous image acquisition also ensures that the subject organs are in the
same exact state in both the low-energy and high-energy image
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1.3.1.2

Clinical Application of DE CT

The utility of DE CT in clinical applications and in pre-clinical research are well-described,
and the accessibility of processed images to users with no additional time or special setup
procedures has facilitated the translation of DE CT into clinical settings.25, 26 For example,
the Sodickson group in the Brigham and Women’s Hospital uses the Dual-source dualdetector Somatom Definition Flash scanner to detect subtle subdural hematoma by
observing the bone-removed images (Figure 1.4).27

Figure 1.4 Bone subtraction for improved conspicuity of hemorrhages. a) A slice from a
conventional CT image from a 75-year-old patient after a fall. b) DE CT produces the
bone-subtracted CT image, confirming a subdural hemorrhage (arrow). c) A conventional
image and d) the bone-subtracted image from a 59-year-old patient with a headache after
a fall indicating a subdural hemorrhage (arrow). The subdural hemorrhages appear subtle
in the conventional images (a, c) but more conspicuous on the corresponding bonesubtracted images (b, d) due to the exclusion of surrounding bone. Reused from reference
with permission from the Radiological Society of North America.26
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While it is challenging to find publications that disclose which DE CT protocols are used
for patient diagnosis or disease management, further clinical applications of DE CT include
assessing pulmonary thromboembolism,28 bone marrow edema,29, 30 gout,31, 32 and vascular
imaging.33-36 Conceivably, the most widely attractive capability of DE CT is that it can
overcome the partial volume effect, specifically using the iodine image, which can indicate
contrast agent localization within soft tissue or bony structures. The partial volume effect
is the averaging of attenuation coefficients in voxels composed of more than one material,
which results in a discrete linear attenuation that actually corresponds to the average of the
attenuation of subvoxel materials (i.e. structures with dimensions smaller than the imaging
resolution), or to that of a border between materials with very different attenuation
properties.37 The presence of subvoxel lesions or vessels can be detected in the iodine
image, which would otherwise not be visible in conventional single energy images.
Specifically, the detection of subvoxel vessels can be useful to track perfusion within
tissues, which can be used to identify regions that have abnormally low blood flow.38, 39

1.3.1.3

Spectral Separation in Micro-CT Scanners

Contrary to most clinical CT filtration techniques, where metal foils are mounted at the
x-ray tube port, a cylindrical shell filter that surrounds the scan bed yet fits within the
scanner bore – controlled by an external filter switcher – has been used to achieve spectral
separation in pre-clinical DE CT. The addition of a mechanism to mount and switch the
filters on the tube port may interfere with the gantry balance and the normal operation of
the scanner. This approach to filtration avoids modifications to the scanner and is
compatible with gantry-based scanners. The cylindrical shell filters the x-rays before and
after the object is scanned, providing a total attenuation that is equivalent to a mounted
filter with the same path length. This technique was demonstrated in an ex vivo study that
successfully decompose soft tissue, bone, and contrast agent in the microvessels into
quantitative images, and is described in Section 1.5.3.40 This technique is also applied in
Chapter 4 of this thesis.
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1.3.2

Material Decomposition Algorithm

DE CT scanners have the capability to produce routine diagnostic images and material
decomposition images.41,

42

Routine diagnostic images are either created through a

combination of the acquired pair of images to produce a blended image that simulates a
standard 120 kVp acquisition, or virtual monochromatic (VMC) images that simulate a
scan that was obtained at a single energy. VMC images can be simulated from 40-140 keV
but commonly provide more reliable attenuation measurements compared to
polychromatic CT. VMC images can be customized to a specific energy level for various
clinical applications, but are commonly 45-55 keV for angiography, 60-75 keV for soft
tissue assessment, or 95-140 keV for metal artifact reduction.41
Material decomposition images calculate the concentrations of each material that would be
necessary to produce the measured attenuation within each image voxel. The effective
linear attenuation coefficient (𝜇) measured in each voxel of a CT image, can be expressed
as a linear combination of the attenuation coefficients of the tissues within the voxel,
multiplied by their volume fraction (𝑓).43 For example, in a voxel containing soft tissue,
iodine, and fat, the linear attenuation of each material (𝜇𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 , 𝜇𝑖𝑜𝑑𝑖𝑛𝑒 , and 𝜇𝑓𝑎𝑡
respectively) contributes to the total linear attenuation coefficient of that voxel 𝜇𝑉 as shown
in Equation 5.
𝜇𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝜇𝑖𝑜𝑑𝑖𝑛𝑒 𝑓𝑖𝑜𝑑𝑖𝑛𝑒 + 𝜇𝑓𝑎𝑡 𝑓𝑓𝑎𝑡 = 𝜇𝑉

(5)

Each voxel is assumed to contain a fraction of soft tissue (𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 ), fat (𝑓𝑓𝑎𝑡 ) and iodine
(𝑓𝑖𝑜𝑑𝑖𝑛𝑒 ).

1.4

Contrast Agents

Contrast agents are commonly administered intravenously for in vivo vascular imaging or
for tissue-specific imaging via passive targeting. After intravenous injection, the contrast
agent in clinical CT is typically present at peak concentrations within minutes, which is
often too short for use with pre-clinical micro-CT scanners that can capture the smallest
blood vessels (i.e. at least 10 minutes of scan time to resolve down to tens of microns). In
addition, small animals, which are commonly used in pre-clinical research, have much
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faster clearance rates than humans. Small-molecule agents clear from the blood pool to the
kidneys within seconds of intravenous administration.44-46 As the Pornrini group
demonstrated, while small-molecule contrast agents can provide high kidney contrast,
these are not ideal for imaging of other tissues or organs.46 For instance, imaging the
vasculature would require long-circulating contrast agents, while hepatic imaging would
require contrast agent localization in the liver.47 Nonetheless, both scenarios require the
evasion of rapid agent clearance from the blood pool through the kidneys.

1.4.1

Iodine-based Contrast Agents

Clinical CT agents are predominantly based on iodine and were primarily developed for
use in radiography. These contrast agents were adapted for use in CT imaging due to their
wide availability and US Food and Drug Administration (FDA) approved status, while preclinical iodinated versions were developed, despite iodine not being an ideal element for
achieving higher contrast in CT or micro-CT imaging.11 Clinical iodinated agents are
divided into four main classes depending on their ionization state (ionic or nonionic) and
whether they are monomeric or dimeric (Figure 1.5).48 Between the two types of ionization
states, ionic agents such as Diatrizoate and Ioxaglate have been shown to be more toxic
and could potentially contribute to contrast media-induced neuropathy once localized in
the kidneys, which makes non-ionic contrast agents (i.e. neutral in charge such as Iohexol
and Iodixanol) more attractive. A contrast agent’s fate once injected into the bloodstream
is determined by electrostatic charge and size.48, 49
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Figure 1.5 Properties of the four classes of iodinated contrast agents. Reused from
reference with permission from Elsevier.48

1.4.2

Size-Dependent Pharmacokinetics of Contrast Agents

The removal of intravenously injected materials from circulation (i.e. clearance) is
determined by the molecule’s size and surface charge.48 The glomerular filtration barrier
(GFB) in the kidneys controls the passage of molecules from the blood pool into the
kidneys. The GFB endothelial cells are electrostatically negative in charge. Hence, it is
believed that molecules with neutral and negatively charged surfaces have much lower
chances of passing the barrier and have higher retention than molecules with positively
charged surfaces. The size of the fenestrations also limits the size of the molecules that can
pass.50 Renal fenestrations can be 6-8 nm in diameter which allow passage of molecules
that are smaller than 6–8 nm (Figure 1.6). Contrast agents that are large enough to evade
renal clearance can potentially exhibit longer circulation times during micro-CT imaging.
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Nanoparticles – materials with diameters in the nanometer range – can either be composed
of polymers with pendent cargo along the chains, or can have a core-shell design, where
the cargo is in the core and is encapsulated by a stabilizing molecule. The cargo is elements
or molecules of interest, which can be contrast agents or drug molecules. As mentioned
previously, for pre-clinical imaging, injected materials must evade renal clearance to have
a chance to circulate in vessels. While renal fenestrations are 6-8 nm in diameter,51 a
conservative size cut off that is used to evade renal clearance is 10 nm.52-54 Hence, to avoid
side effects that may be associated with kidney accumulation or to accomplish extrarenal
functions, such as blood pool imaging, tumor imaging or drug delivery, nanoparticles larger
than 10 nm in size are typically studied. On the other hand, a variety of upper size limits
have been declared for intravascular applications to avoid blood flow interruption in the
smallest vessels,55 with the least conservative being an upper size restriction of 1 µm.56
However, an upper size limit of 200 nm is commonly reported due to the success of smaller
nanoparticles entering abnormal tissues with increased vascular permeability and altered
interstitial environment.57-59
The reticuloendothelial system (RES) is responsible for removing nanoparticles that are
larger than 10 nm. The reticuloendothelial system (RES) is composed of phagocytic and
pinocytic cells that are found in the blood pool and within tissues, and is responsible for
removing foreign material from vascular circulation.60, 61 The RES includes phagocytic
monocytes in the blood, and macrophages in connective tissue, lymphoid organs (e.g.
spleen), bone marrow, bone, liver, and lung, and pinocytic liver sinusoidal endothelial
cells. The RES sequesters removed materials into the liver, spleen and lungs, based on the
nanoparticle’s size, shape and surface charge (Figure 1.6).62 For instance, nanospheres
were found to evade clearance longer than nanocylinders and nanodiscs, with dominant
clearance by the liver, as previously demonstrated in rigid metal core nanoparticles.63
While biodistribution differences have been attributed to geometry-dependent flow
characteristics,63 it is undeniable that the surface area to volume ratio of these nanoparticles
influence their exposure to clearance mechanisms, and the fact that nanospheres have lower
ratios potentially decrease their chances of being detected. The electrostatic charge also
affects clearance rates, where positively charged nanoparticles are easily detected by RES
cells, which are inherently negatively charged.
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Figure 1.6 The physical properties of nanoparticles and their effect on tissue accumulation.
a) Spherical nanoparticles that are larger than 150 nm accumulate readily in the lung
microvessels, liver and spleen. The kidneys clear the smallest nanoparticles.51 b) The shape
of nanoparticles can affect their localization, due to morphology-related flow
characteristics that substantially alter circulating lifetimes, cell membrane interactions and
macrophage uptake.63 c) Surface electrostatic charge influences opsonization, circulation
times, and interaction with resident macrophages of RES organs, where positively charged
particles are more prone to clearance by macrophages in the lungs, liver and spleen. Neutral
and slightly negatively charged nanoparticles have longer circulation lifetimes and lower
RES clearance rates.64 Reused from reference with permission from Springer Nature.62

1.4.3

Polyethylene Glycol in Intravenous Applications

In the 1970s, appending a fragment of PEG to nonhuman bioactive proteins for therapy
was found to substantially reduce the adverse immunological responses produced by these
proteins.65, 66 By coupling the proteins with a methyl-terminated PEG (mPEG), researchers
also found that the circulation times of the short-lived human derived proteins were
improved. Thus, modification of proteins with PEG – referred to as PEGylation – provided
a pathway for the development of protein pharmaceuticals.67-73 PEGylation was also
extended to novel drug delivery carriers, such as nanoparticles and liposomes, to overcome
their RES uptake, leakage of cargo, colloidal stability, and tissue toxicity. Specifically, by
evading renal clearance and RES uptake, and demonstrating colloidal stability in the blood
pool, PEGylated materials can have long residence times in the vasculature and have a
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higher chance of arriving at their target destinations.74-79 The most reliable strategy to
prevent cellular recognition and protein adsorption is the immobilization of PEG at the
particle surface. PEG is an ideal hydrophilic polymer with a flexible, unbranched structure,
and terminal hydroxyl groups available for activation and linking to proteins and particles.
Hydrophobic particles are removed faster from circulation than hydrophilic particles, due
to their colloidal instability in the blood pool and affinity to immune system markers that
promote their removal from circulation.80-82 Several therapeutic drugs (e.g. paclitaxel,
doxorubicin) are hydrophobic, and contrast elements (e.g. iodine, gadolinium) are
commonly incorporated into hydrophobic nanoparticles. The detection of nanoparticles by
the immune system via protein markers (e.g. opsonin) occurs with greater affinity on
hydrophobic surfaces than on hydrophilic surfaces, facilitating RES clearance.80 Stealth
shielding on the surface can reduce the recognition of these particles, increasing circulation
time from a few seconds to hours.83 Instead of the direct PEGylation of hydrophobic
surfaces, stabilization can be achieved by adsorption or chemical binding of amphiphilic
molecules.84-87 An amphiphilic molecule comprises a hydrophobic part, such as a lipid that
will interact with the hydrophobic cargo, and a hydrophilic part, such as PEG, that
protrudes into the aqueous environment to protect the cargo from immune system
detection. Various designs have been explored to achieve prolonged circulation times of
nanoparticles using amphiphilic molecules (Figure 1.7). Stabilized liposomes, or PEGcoated liposomal nanoparticles (Figure 1.7B) have been demonstrated to achieve
prolonged circulation times.88 These nanoparticles been dubbed as stealth liposomes and
can be fabricated using lipid conjugates of PEG, such as PEG-destearoylphosphatidylethanolamine (PEG-DSPE).88
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Figure 1.7 a) Schematic representation of amphiphilic lipids. I) Amphiphiles consist of
hydrophilic and hydrophobic portions. Examples include II) micelle-forming lipids, III)
bilayer-forming lipids, IV) PEG–lipids, and (V) cholesterol. b) Amphiphiles can be used
to form assemblies such as I) micelles, II) conventional liposomes III) PEG- or cholesterolstabilized liposomes, IV) microemulsions, V) micelles containing a hydrophobic core, and
VI) bilayers on metal or metalloid nanoparticles. Reused from reference with permission
from John Wiley and Sons.89
A wide range of polymer synthesis techniques are now available and permit the fabrication
of polymers with diverse properties,90 including customized chain lengths,91 the capacity
to link functional groups or cargo for specific in vivo purposes,92 amphiphilicity through
polymer conjugation,93 and even the ability to degrade upon exposure to specific stimuli.94
While the initial development of in vivo agents was dominated by liposomal formulations
or PEG-linked lipids, there has been a recent surge in nanoparticles encapsulated with
amphiphilic diblock copolymers, containing hydrophobic cargos. Therapeutic drugs have
been predominantly reported as cargo of such carriers, and some metal-core nanoparticles
that have been synthesized with hydrophobic surfaces can also be encapsulated and have
been shown to achieve prolonged circulation times in small animals. In these polymers,
PEG is coupled with hydrophobic polymers such as polylactide, polycaprolactone, or
poly(propylene glycol).95-97
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1.5
The Development of Nanoparticle-Based Contrast
Agents for Micro-CT
1.5.1

Commercially Available Pre-Clinical Agents

The prolonged circulation times of nanoparticle-based therapeutics, and their abilities to
target the liver instead of the kidneys, have inspired the development of nanoparticle-based
contrast agents. There are commercially available contrast agents that are used for preclinical imaging by micro-CT, and these are based on iodine, alkaline earth metals, and
gold (Figure 1.8).
MediLumine’s Fenestra LC and VC are composed of oil-in-water lipid nanoemulsions
composed of the polyiodinated triglyceride 1,3-bis-[7-(3-amino-2,4,6-triiodophenyl)heptanoyl]-2-oleoyl glycerol, which contains 50 mg/mL of iodine (Figure 1.8a), while
Miltenyi Biotec currently has agents containing greater iodine concentrations of at least
120 mg/mL composed of iodinated small molecules or covalently bound iodine on a
polymer backbone (Figure 1.8b). Alkaline earth metal nanoparticles – identified as barium
in some publications98, 99 – were developed by the same company and provide promising
CT contrast and circulation times. Like their drug delivery vehicle analogues, nonPEGylated nanoparticles containing iodine evaded renal clearance and localized in the
liver, making excellent liver contrast agents (i.e. Fenestra LC), while small molecule agents
localize in kidneys for renal imaging (Figure 1 8). Once coated with PEG, long circulation
times were observed in small animals. In particular, Fenestra VC, ExiTron nano 6000,
ExiTron nano 12000, and AuroVist 15 nm (Figure 1.8c) demonstrate high contrast in the
blood pool for hours, which well exceeds micro-CT imaging. AuroVist 15 nm and 1.9 nm
can contain up to 200 mg/mL of gold nanoparticles in saline.
Unlike clinically available agents, the companies that manufacture these pre-clinical agents
do not make the precise chemical formulations, let alone the nanoparticle type, available,
which makes it difficult to predict their performance as micro-CT agents. For instance, the
structures of Binitio Biomedical’s eXIA NANO, eXIA 160/160XL, and eXUS, which are
pre-clinical micro-CT agents based on barium, iodine, and an unknown element,
repectively,100 are not readily available to non-customers, although some of their structures
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have been stated in previous publications.101, 102 Comprehensive studies comparing the
vascular contrast enhancement, circulation time, and biodistribution of these contrast
agents have been reported,101,

103

so scientists may purchase agents that cater to their

research requirements.

Figure 1.8 Visual representations of commercially available pre-clinical agents.
a) Fenestra LC from MediLumine is an oil-in-water lipid nanoemulsion composed of
polyiodinated triglycerides, and its PEG-coated version is Fenestra VC.104 b) The iodinated
ExiTron U, P, and V from Miltenyi Biotec represent the molecular micro-CT agents that
are available. The ExiTron nano 6000 and 12000 are alkali earth metal nanoparticle agents
that are also supplied by Miltenyi Biotec. c) Nanoprobes specializes in gold nanoparticle
agents and fabricate AuroVist 1.9 nm and 15 nm for micro-CT imaging. Schematics and
cartoons of the ExiTron series were based on product descriptions from Miltenyi Biotec,105
and the structure for Fenestra LC and VC, and AuroVist were based on descriptions or
illustrations from MediLumine106 or Nanoprobes,107 respectively.
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1.5.2

Metal-Based Contrast Agents

Over the past several years, metal nanoparticle agents have been developed that incorporate
a wide variety of elements for CT imaging. The most commonly studied metal
nanoparticles for micro-CT consist of gold. Gold nanoparticles produce greater CT
enhancement than iodinated agents because of the high atomic number of gold.108, 109 Gold
nanoparticles are particularly promising for in vivo imaging applications – hence the
availability for purchase – because gold is very inert and gold nanoparticles can be readily
synthesized and modified with several types of surface-linked molecules to render them
biocompatible.110, 111 While its provides the highest contrast for all x-ray energies relevant
due to its high density, its K-edge of 80.7 keV falls in the middle of the clinical CT spectra
and closer to the upper limit of most in vivo micro-CT scanners, making it less ideal than
other metals for DE micro-CT imaging.
Apart from gold, metal-based agents such as transition metals have been reported. A recent
study by Chakravarty et al. presented the fabrication and characterization of PEG-coated
tantalum oxide nanoparticles by a sol–gel method (Figure 1.9a).112 One of the synthesized
agents can provide vascular contrast in micro-CT images (> 50 HU) for at least 3 hours
when using a peak voltage of 90 kVp. Although tantalum is high density and has a K-edge
of 67 keV, its K-edge is still slightly higher than the average micro-CT energies (i.e. 50-60
keV).
Another class of metals that is ideally suited for micro-CT is the lanthanides (e.g.
gadolinium, erbium).11 They have k edges of 38-64 keV,113 some of which coincide with
the peaks of the x-ray energy distributions typically used in high-resolution in vivo microCT scanners. The ideal position of the K-edges offers potential to increase contrast
attenuation for single-energy micro-CT scans11 and, more importantly, offers the
opportunity to match the available x-ray spectrum and contrast agent in dual-energy
micro-CT.114
Lanthanide agents designed for in vivo vascular micro-CT are not commercially available,
but studies are emerging demonstrating the utility of PEG-modified lanthanide
nanoparticles in microimaging.115-118 To prepare lanthanides that can be used in the in vivo
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milieu in small animals, common methods include the use of clinically-available MRI
agents to formulate nanoparticles that evade rapid renal clearance, or the synthesis of
hydrophobic lanthanide nanoparticles encapsulated within a shell of phospholipid-polymer
conjugate molecules (i.e. liposomes or lipid nanoparticles). For instance, Liu et al.
demonstrated that DSPE-PEG can be used to encapsulate sodium ytterbium tetrafluoride
nanoparticles at a concentration of 70 mg/mL. The resulting agent provides high vascular
contrast for at least 20 minutes when imaging at a tube potential of 120 kVp
(Figure 1.9b).108 Although ytterbium has a K-edge of 61.3 keV, which is slightly higher
than mean energies of the micro-CT spectrum, any synthesis method that is presented for
lanthanides is transferrable to the rest of the elements within the series due to their very
similar chemistry. However, like other lanthanide contrast agent publications that
demonstrate the utility of polymer-encapsulated lanthanides in micro-CT,115,

116

their

lanthanide concentrations need improvement as the agents have typically only been
formulated at less than 100 mg/mL of lanthanide (i.e. 1 g/kg body weight in small animals).

Figure 1.9 Nanoparticle design of long-circulating a) tantalum- and b) ytterbium-based
contrast agents that provide high vascular contrast in micro-CT images of live mice. The
ytterbium nanoparticles were encapsulated within DSPE-PEG and have been used to
fabricate stealth liposomes,88 and the PEG-coated tantalum-based nanoparticles were
prepared using the sol-gel method. Reused from publications with permission from RSC
Publishing and Wiley-VCH (Germany).112, 115
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1.5.3

DE Micro-CT Using Metal-Based Agents

Of the metal nanoparticles that have been reported, gold and metals from the lanthanide
series have been used in DE micro-CT. Despite the K-edge of gold being too high (81 keV)
for ample spectral separation in a large installed base of micro-CT scanners, it can separate
low and high energy photons sufficiently in clinical scanners that use 80 and 140 kVp. It
has also been demonstrated to perform well when using 40 and 80 kVp photons, which
most micro-CTs are capable of producing.119 In this latter case, it functioned similarly to
iodine, where a decrease in attenuation was observed with higher energy photons. Rather
than using the K-edge property of the contrast element, the high density of gold was taken
advantage of to decompose tissue volumes.
In pre-clinical research using small animals, K-edge DE decomposition has been
demonstrated successfully by ex vivo agents using lead- and lanthanide-based contrast
agents. The lead-based Microfil MV 122 (Flowtech Inc, USA), which is a commercially
available ex vivo contrast agent, is widely used in pre-clinical research. By using the Kedge of lead at 88 keV, material-specific decomposition that utilized x-ray spectra below
and above the K-edge (i.e. using 96 and 140 kVp photons) was demonstrated.120 Microfil
is used in pre-clinical studies that image the vasculature with single-energy micro-CT,121123

but as for DE imaging, its K-edge may be more ideal for clinical scanners. In addition,

the toxicity of lead does not make it a feasible in vivo contrast element, nor does it make it
ideal for ex vivo purposes due to handling hazards for the researchers.
Recently, an ex vivo agent that is analogous to Microfil was developed, except it contains
erbium, which is a lanthanide, instead of lead.124 Lanthanides have K-edges between 38
and 64 keV that fall in the middle of the energy range most high-resolution in vivo microCT scanners produce. 113 When using lanthanides in DE imaging, K-edge decomposition
can be performed. These K-edge energies also coincide with mean energies most single
energy CT or micro-CT imaging protocols use. The erbium-based ex vivo agent was
composed of nanoparticles with diameters in the nanometer range (i.e. nominal diameter
in the tens of nm), and hence did not extravasate from the vessels when perfused
intravenously post-mortem. Moreover, the use of a curing agent permitted the agent to
remain in the lumen, such that CT contrast values of at least 4000 HU were measured in
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the inferior vena cava of mice. The K-edge of erbium at 57.5 keV permitted K-edge
decomposition when used in DE micro-CT scans of rat hindlimbs (Figure 1.9).114 The DE
images were acquired with erbium-filtered 70 kVp and copper-filtered 90 kVp, with the
goal of using the filters to optimize spectral separation by minimizing the overlap between
the photon distributions. While the DE study obtained the scans sequentially, the filters are
controlled by an automatic filter switcher that is capable of fast filter switching for
interleaved scans in vivo. Contrary to most clinical CT filtration techniques, where metal
foils are mounted at the x-ray tube port, a cylindrical shell filter that surrounds the scan bed
yet fits within the scanner bore was controlled by an external filter switcher. The addition
of a mechanism to mount and switch the filters on the tube port may interfere with the
gantry balance and the normal operation of the scanner. This approach to filtration avoids
modifications to the scanner and is compatible with gantry-based scanners. The cylindrical
shell filters the x-rays before and after the object being scanned, providing a total
attenuation that is equivalent to a mounted filter of with the same path length.
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Figure 1.10 DE CT results from a rat hindlimb perfused with an erbium-based ex vivo
agent. b) low- and b) high-energy images are decomposed into quantitative c) bone- and
d) vessel volumes. This figure was taken from an article by Tse et al,114 published under
the Creative Commons (CC BY 4.0) - Gold Open Access.
Gadolinium is another lanthanide and is used as a contrast agent in MRI. Gadovist, which
is a clinical MRI contrast agent containing 157 mg/mL of gadolinium, was used in a recent
study that used DE micro-CT to develop a quantitative measure of contrast agent
accumulation in soaked tissues.125 By using unfiltered 70.1 kVp and calcium-filtered
140 kVp, regions in the esophagus and airways where gadolinium had accumulated were
identified. While Gadovist can be used in micro-CT scans of the kidneys in vivo due to its
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rapid renal clearance rates, the agent cannot be used to visualize the vasculature and tissues
despite its high gadolinium loading and will likely accumulate at toxic doses in kidneys.
Additionally, in ex vivo and in situ imaging, although small molecule agents permit the
observation of parenchymal tissue as demonstrated by the Gadovist soaking study, only a
negative opacification of the vessels in micro-CT images will be observed. This is due to
their small size, enabling the extravasation from the vasculature.
While ex vivo studies in tissue specimens and small animals post-mortem can be beneficial
to pre-clinical research, being able to study subjects in vivo can provide physiological
information and longitudinal evidence that are essential to studying disease and drug
development. The objective of my thesis work was to develop a lanthanide-based contrast
agent that can be used for DE micro-CT of small animals in vivo. Advancements in
nanotechnology and polymer sciences were taken advantage of to develop a longcirculating, nanoparticle-based contrast agent that contains at least 100 mg/mL of
lanthanides that provides vessel opacification in micro-CT images, and permits K-edge
decomposition of DE images in live mice.

1.6

Thesis outline

In this thesis, (1) I developed a novel lanthanide nanoparticle agent composed of higherbium content nanoparticles, and an optimized amphiphilic polymer that contains PEG,
(2) explored an alternative design composed of individually-coated gadolinium
nanoparticles to improve subject viability, and (3) demonstrated the utility of the novel
contrast agent in DE imaging of live mice by using a cylindrical shell controlled by a fast
filter switcher, to obtain interleaved scans. The ultimate results of each chapter are
summarized as follows.
Chapter 2 describes the synthesis of assemblies of erbium nanoparticles encapsulated in
micelles composed of PEG-containing amphiphilic block copolymers. A library of
amphiphilic block copolymers was investigated and included copolymers which were
either purchased or synthesized in customized lengths. The colloidal stability was observed
in vitro by dynamic light scattering measurements of the diameter in water, saline and a
mouse serum mimic, and erbium concentrations were measured by inductively-coupled
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plasma mass spectrometry. PEG-poly(lactic acid) as the coating polymer provided the most
promising in vitro characteristics and was used to concentrate 100 mg/mL of erbium for
intravenous injections of mice. The injected subjects were imaged by micro-CT and CT
contrast enhancements of over 250 HU was observed in the vasculature for at least an hour,
which well exceeds in vivo micro-CT scan time requirements. This work, entitled “Polymer
assembly encapsulation of lanthanide nanoparticles as contrast agents for in vivo microCT,” was published in Biomacromolecules in February 2018. To our knowledge, this is the
first demonstration of the successful synthesis of an in vivo micro-CT blood pool agent that
can be dispersed into colloidally stable assemblies containing 100 mg/mL of erbium.
For Chapter 3, in lieu of using an amphiphilic polymer to encapsulate multiple
nanoparticles within micelles cores, I altered the contrast agent design so that PEG was
grafted onto the nanoparticle surface directly and smaller particles were synthesized. These
modifications were done to improve the viability of the mice that were injected with the
contrast agent, to permit longitudinal studies of the same subjects. While our formulation
in chapter 2 permitted survival for up to 2 days, the new formulation permitted survival for
at least 5 days and caused toxicity only to the spleen. CT contrast enhancements of at least
245 HU was observed in the blood pool, which slowly started decreasing at least 10
minutes after injections. This study, entitled “PEG-modified gadolinium nanoparticles as
contrast agent for in vivo micro-CT,” will be submitted this fall. To our knowledge, like
Chapter 2, this is the first demonstration of the successful synthesis of an in vivo micro-CT
blood pool agent that can be dispersed into colloidally stable assemblies containing
100 mg/mL of gadolinium, and also reports the effects of high intravenous doses of
gadolinium (i.e. 20 mg per subject) on mouse tissues 5 days after a single injection.
Chapter 4 describes the feasibility of in vivo DE micro-CT using the contrast agent that
was formulated in Chapter 2. I optimized the pair of spectra that were used to obtain the
DE images using SPEKTR 3.0. DE decomposition of the acquired images into quantitative
soft tissue, bone and gadolinium-containing vessel volumes are demonstrated. This work
is entitled “In vivo dual energy micro-computed tomography imaging of the mouse
vasculature using gadolinium nanoparticles as contrast agent” will be submitted in the fall,
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and is the first demonstration of an in vivo DE CT technique using a lanthanide-based
contrast agent, which can be used with any pre-clinical, gantry-based micro-CT scanner.
Chapter 5, is a summary of the main objectives and results of Chapters 2 through 4.
Additionally, I present future research opportunities that may benefit from the work that is
presented within this thesis.
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Chapter 2

2

Polymer Assembly Encapsulation of Lanthanide
Nanoparticles as Contrast Agents for In Vivo Micro-CT

Despite recent technological advancements in microcomputed tomography (micro-CT) and
contrast agent development, pre-clinical contrast agents are still predominantly iodine
based. Higher contrast can be achieved when using elements with higher atomic numbers,
such as lanthanides; lanthanides also have x-ray attenuation properties that are ideal for
spectral CT. However, the formulation of lanthanide-based contrast agents at the high
concentrations required for vascular imaging presents a significant challenge. In this work,
we developed an erbium-based contrast agent that meets micro-CT imaging requirements,
which include colloidal stability upon redispersion at high concentrations, evasion of rapid
renal clearance, and circulation times of tens of minutes in small animals. Through
systematic studies with poly(ethylene glycol) (PEG)-poly(propylene glycol), PEGpolycaprolactone, and PEG-poly(L-lactide) (PLA) block copolymers, the amphiphilic
block copolymer PEG114-PLA53 was identified to be ideal for encapsulating oleate-coated
lanthanide-based nanoparticles for in vivo intravenous administration. We were able to
synthesize a contrast agent containing 100 mg/mL of erbium that could be redispersed into
colloidally stable nanoparticles in saline after lyophilization. Contrast enhancement of over
250 HU was achieved in the blood pool for up to an hour, thereby meeting the requirements
of live animal micro-CT.

2.1 Introduction
With the ultimate goal of developing methods to treat human disease, small animal models
are used extensively in cardiovascular, orthopedic, and cancer research.1-3 The advantages
of using small animals include short gestation times, low maintenance costs and ease of
genetic manipulation.4 In order to study disease at scales suitable for small animals, highresolution imaging techniques (i.e., micro-imaging) have been developed; these include
micro magnetic resonance imaging,5,

6

micro positron emission tomography,7 micro-

ultrasound,8, 9 and micro computed tomography (micro-CT).10 Among these, micro-CT has
been the most utilized, based on scientific publications in the last five years.
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Micro-CT’s ubiquity is attributable to the fact that the modality is quantitative, threedimensional, non-destructive, fast and cost-effective. Contrast in micro-CT is derived from
the differential attenuation of x-rays by various tissues. Unfortunately, soft tissues, which
have similar densities, have little differential CT contrast and exogenous agents are
required to provide contrast. For example, to image the vasculature, x-ray attenuating
contrast agents are injected intravenously to “opacify” the vessels during the acquisition of
the micro-CT scan. With these contrast agents, vascular imaging by micro-CT can be
potentially utilized to reliably track the development of blood vessels during the process of
angiogenesis and in studying the effect of novel therapies for re-vascularization.11 For
human imaging, CT contrast agents are typically small iodinated molecules, which are
cleared within a few minutes through the renal system. However, micro-CT scan times
can be as long as tens of minutes and successful imaging of the vasculature requires the
use of contrast agents that clear from the blood over extended time periods. These agents
are referred to as “blood pool” contrast agents.
Several CT blood pool contrast agents are available commercially for in vivo small animal
research.12, 13 These have been made possible by advances in nanotechnology and consist
of particles large enough to evade immediate renal clearance (i.e. > 10 nm).14 Initially,
commercially available nanoparticle-based blood pool contrast agents were iodine-based
to take advantage of the strong attenuation of iodine at low energies (K-edge = 33.2 keV)
and included Fenestra VC (containing 50 mg/mL of iodine) and eXia 160 XL (containing
160 mg/mL of iodine).13, 15 More recently gold-based agents have been developed (e.g.
AuroVist 15 nm, containing 200 mg/mL of gold), which take advantage of the high density
of gold.16 These agents have been developed with the intent to deliver a high loading of
metal (x-ray attenuator) in a small volume of contrast agent and thereby to provide higher
contrast between the vessels and surrounding tissue.
Another class of metals appropriate for CT contrast agents is the lanthanides. These
elements are of particular interest because they have K-edges near the average energies
used in micro-CT (between 80 kVp and 120 kVp). This property makes the lanthanides
ideally suited to use with specialized micro-CT techniques that take advantage of the
spectral properties of materials, such as dual-energy imaging and spectral CT. Of the
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lanthanides, gadolinium has been used most extensively as a contrast agent for magnetic
resonance imaging (MRI). Polymeric nanoparticles decorated with gadolinium, such as the
chelated derivative of diethylenetriaminepentaacetic acid and Gd(III) on a cross linked
polymer nanogel, have been synthesized and used for vessel imaging of mice, but have
gadolinium loading that is too low for CT imaging (typically < 0.5 mg/mL).17-19
Lanthanide-based nanoparticles have also been explored for imaging, largely due to their
abilities to alter proton relaxation times in MRI in the case of gadolinium20, 21 or their
photon upconversion capabilities in the case of NaLnF4 (where Ln is a lanthanide and the
system is co-doped).22-24 However, such particles are usually synthesized with hydrophobic
ligands,25 making it challenging to disperse them with high stability in blood. Chatterjee et
al. achieved this by coating lanthanide-based nanoparticles with polyethyleneimine,
reaching concentrations of 4.4 mg/mL (used subcutaneously for upconversion
luminescence imaging).22 Budijono et al. explored the encapsulation of lanthanide-based
nanoparticles in block copolymer assemblies, and demonstrated the stability of these
assemblies in serum media at low concentrations (< 1 mg/mL).24 Similary, Zhu et al. used
pH-responsive block copolymers to encapsulate gadolinium-based nanoparticles, and
demonstrated that it can stabilize the nanoparticles in aqueous solution at low
concentrations (< 0.1 mg/mL).21 However, to date only Liu et al., have synthesized a
lanthanide contrast agent with a concentration high enough for micro-CT imaging.26 They
encapsulated

70 mg/mL

of

ytterbium

in

1,2-distearoyl-sn-glycero-3-

phosphoethanolamine-terminated poly(ethylene glycol) (PEG) and demonstrated
circulation in the blood pool for approximately 20 minutes. However, even higher
lanthanide concentrations and blood circulation times are required for high resolution
imaging of the vasculature.
In this study, we present a simple and systematic method to prepare a lanthanide-based
contrast agent for micro-CT applications, which require high contrast-element loading
(> 100 mg/mL preferred) and long circulation times (ideally > 30 minutes). The high
lanthanide concentration poses a significant challenge, particularly when paired with the
need to add polymers, which are required to achieve long circulation times. Erbium, which
we have demonstrated to be an excellent contrast agent for ex vivo imaging, was selected

42

as the lanthanide.27 Oleate-coated NaErF4 nanoparticles (ErNP) were synthesized and
encapsulated into core-shell nanoassemblies via nanoprecipitation using a series of
amphiphilic block copolymers (Figure 2.1). A sequence of optimization steps was then
performed to identify an ideal polymer, which encapsulates a high lanthanide content while
remaining colloidally stable after redispersion in saline and a mouse-blood mimic. Once
the ideal polymer was identified, the lanthanide-based contrast agent was evaluated in vivo
over a period of one hour. To our knowledge, this is the first demonstration of the
successful synthesis of an in vivo lanthanide-based blood pool agent that can be dispsersed
into colloidally stable assemblies containing 100 mg/mL of erbium.

Figure 2.1 Schematic representation of self-assembled erbium-based nanoparticles as a
pre-clinical blood pool contrast agent.

2.2
2.2.1

Experimental Section
Materials and General Methods

Reagents were purchased from commercial suppliers as described in Appendix A and were
used without further purification unless otherwise noted. Methods used in the synthesis and
characterization of the materials are also presented in Appendix A.

2.2.2

Nanoprecipitation
for
Self-Assembly
of
Nanoparticles Containing Erbium Nanoparticles

Polymeric

Erbium nanoparticles (ErNP) were synthesized by a previously reported method.28, 29 The
ErNP were self-assembled with purchased poly(ethylene glycol) (PEG)-poly(propylene
glycol) (PPG) triblock copolymers (PEG76-PPG22-PEG76 and PEG137-PPG34-PEG137 where
the subscripts indicate the degree of polymerization of the blocks), or synthesized diblock
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copolymers of PEG-poly(-caprolactone)(PCL) (PEG45-PCL20, PEG45-PCL51, PEG114PCL51, PEG114-PCL97) or PEG-poly(l-lactide) (PEG45-PLA25, PEG45-PLA52, PEG114PLA53, PEG114-PLA122).30, 31 ErNP (2 mg) were dissolved in 0.1 mL of tetrahydrofuran
(THF). Separately, 8 mg of copolymer was dissolved in 0.1 mL of THF. These solutions
were then combined and added dropwise to 1.8 mL of deionized water under magnetic
stirring. After 1 hour, stirring was stopped and the solution was left uncapped for 12 hours
to allow for organic solvent evaporation. The solutions were then dialyzed against 100 mL
of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to
remove large aggregates and the samples were characterized by dynamic light scattering
(DLS), transmission electron microscopy (TEM) and inductively coupled plasma mass
spectrometry (ICP-MS).

2.2.3

Colloidal Stability of the Polymeric Nanoparticles

The sterile polymeric nanoparticles containing ErNP were lyophilized prior to redispersion
in saline. Saline is used as the solvent of the NPs prior to intravenous injection in vivo
because it is isotonic with blood; therefore the particles must remain colloidally stable in
that environment. DLS size measurements were performed on the redispersed ErNP and
the average sizes of the samples were observed for up to one hour.

2.2.4

Varying the Polymer Content of the Nanoparticles

The polymeric nanoparticles containing ErNP that remained colloidally stable after freezedrying and redispersion in saline, and that encapsulated relatively higher erbium amounts
were selected (PEG114-PLA53). Solutions with varying mass ratios were prepared.
Synthesized ErNP (80 mg dissolved in 4 mL of THF) were added to 320, 160, 80 or 40 mg
of PEG114-PLA53 in 4 mL of THF. These solutions were combined and added dropwise to
100 mL of deionized water under magnetic stirring. After 1 hour, stirring was stopped and
the suspension was left uncapped for 12 hours to allow for organic solvent evaporation.
The suspensions were then dialyzed against 500 mL of deionized water for 2 days with 5
solvent changes. A 450 nm syringe filter was used to remove large aggregates and the
samples were characterized by DLS, TEM and ICP-MS. The samples were lyophilized,
sterilized and re-dispersed in 400 µL of saline. 10 µL of the samples were added to 990 µL
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of saline or mouse serum mimic for an hour-long time-course DLS study. The mouse serum
mimic was pH 7.4 phosphate buffered saline containing 0.5 µg/mL mouse
immunoglobulins, 1 wt% bovine serum albumin and 0.1 wt% sodium azide. Colloidal
stability in a mouse serum mimic in vitro will serve as an indicator of its stability in vivo;
an increase in the average size signifies aggregation, which would lead to immune system
detection followed by clearance from the blood pool in vivo.

2.2.5

General Micro-CT Imaging and Analysis Methods

Micro-CT images were acquired using the GE Locus Ultra (London, ON) with a protocol
previously used to evaluate contrast agent distribution in vivo.15, 32 Briefly, 1000 views
(16 ms per view) were acquired at 80 kVp, 55 mA over 360 and reconstructed using a
cone-beam reconstruction algorithm. The resulting images have a voxel size of
150 x 150 x 150 µm. Images were analyzed using MicroView (Parallax Innovations,
London, ON) and CT contrast was reported in Hounsfield Units (HU – a standard linear
scale of x-ray attenuation coefficient, where air = -1000 HU and water = 0 HU). All HU
values were measured over a volume of 450 × 450 × 150 µm.

2.2.6

Micro-CT Imaging
Nanoparticles

of

Erbium-Containing

Polymeric

The relationship between CT contrast and erbium concentration was first determined by
micro-CT. Erbium chloride was diluted in saline at erbium concentrations of 5, 10, 20 and
100 mg/mL, which acted as calibration standards. The linear regression between CT
contrast (in HU) and erbium concentration was then used to measure the erbium
concentrations resulting when 40 mg of each of the lyophilized 1:1 and 0.5:1
PEG114-PLA53:ErNP formulations were separately dispersed in 0.2 mL of saline.

2.2.7

Toxicity of the Contrast Agent

The 1:1 and 0.5:1 PEG114-PLA53:ErNP mass ratio formulations were tested. Details of
these experiments are described in Appendix A. Briefly, an in vitro cell viability assay was
done using C2C12 mouse myoblast cells from Millipore Sigma (Oakville, ON). The cells
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were incubated with the contrast agent for 24 hours, after which cell viability was measured
using a 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Following in vitro tests, the in vivo toxicity of the contrast agent was evaluated using the
dorsal interscapular subcutaneous tissue of C57BL/6 male mice (25-32 g). All animal
studies were carried out in accordance with the regulations set out by the University of
Western Ontario’s Council on Animal Care, in agreement with the ARRIVE guidelines,
and were carried out in accordance with the U.K. Animals Act, 1986 and associated
guidelines.

2.2.8

Intravenous Administration of the Contrast Agent and
Characterization of Distribution In Vivo

Five C57BL/6 male mice (25-32 g) were anesthetized initially with 4% isoflurane, and then
1.5% for maintenance, in O2 via a nose cone placed on the snouts of the animals. The tail
veins were catheterized using PE-20 polyethylene tubing. For each mouse, images were
first acquired prior to contrast administration. The contrast agent (0.2 mL at 1 g/kg body
weight) was injected over a period of 3 minutes and three scans were acquired, starting 2
minutes following the end of injection and ending 60 minutes post injection. The 1:1
PEG114-PLA53:ErNP (mass ratio) was tested in 3 mice and the 0.5:1 mass ratio formulation
was evaluated in 2 mice.

2.3
2.3.1

Results and Discussion
Synthesis and Characterization of Oleate-Coated ErNP

NaErF4 nanoparticles were synthesized based on a previously reported method.28, 29 DLS
measurements of ErNP in THF reported a Z-average diameter of 50 ± 1 nm and a
polydispersity index (PDI) of 0.18 ± 0.02 (Figure 2.2a and Figure A.2, Appendix A). These
results were supported by TEM imaging, which confirmed the synthesis of spherical
nanoparticles (Figure 2.2b).
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Figure 2.2 a) Volume diameter distribution of ErNP in THF measured by DLS. b) A TEM
image of the oleate-coated ErNP.

2.3.2

Synthesis and Characterization of Diblock Copolymers

The ErNP are oleate-coated, which makes them incompatible with the aqueous blood
pool.33 It was envisioned that by nanoprecipitation of the ErNP with amphiphilic block
copolymers, assemblies containing hydrophobic ErNP in the hydrophobic polymer cores
and hydrophilic stabilizing polymer coronas would be formed (Figure 2.1). Polymers are
relatively easy to prepare, are colloidally stable even at low concentration, and can be
synthesized at different lengths using various monomers, making them tunable and
versatile materials.34 We used PEG as the hydrophilic block for its well-known stealth
properties against the immune system.35, 36 In lieu of displacing the oleate on the ErNP
surface with polymers,29,
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we chose to synthesize polymeric micelles by

nanoprecipitation, which is a fast, reproducible, and cost-effective means of suspending
hydrophobic cargo in polar solvents.38 Displacing the oleate on the ErNP surface would
favor the suspension of individual nanoparticles in solution, which is not a requirement in
micro-CT.
To identify a carrier that would encapsulate high erbium content while surviving
lyophilization and redispersion in saline, a series of amphiphilic block copolymers was
studied (Figure 2.3, Table 2.1). Two PEG-PPG-PEG triblock copolymers (commonly
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referred to as poloxamers), which are commercially available, cost-effective and are FDAapproved for intravenous administration in humans, were used to form the polymeric
assemblies.39 In addition, several block lengths of PEG-PCL and PEG-PLA were
synthesized and studied. These diblock copolymers were selected because they are used
clinically as therapeutic drug carriers and are also currently in further clinical trials. 40 The
characteristics of the polymeric micelles may change upon varying the copolymer’s
properties (i.e. hydrophobicity of the non-polar block, total block length, and PEG ratio).41

Figure 2.3 Chemical structures of the amphiphilic block copolymers that were used to form
the polymeric assemblies.
Table 2.1 SEC and 1H NMR characterization results of diblock copolymers. aDetermined
by 1H NMR spectroscopy; bDetermined by SEC.
Copolymer
PEG76-PPG22-PEG76
PEG137-PPG34-PEG137
PEG45-PCL20
PEG45-PCL51
PEG114-PCL51
PEG114-PCL97
PEG45-PLA25
PEG45-PLA52
PEG114-PLA53
PEG114-PLA122

PEG
molar
mass
(g/mol)
6700
12000
2000
2000
5000
5000
2000
2000
5000
5000

Monomer
feed
(equiv.)
18
35
44
88
22
44
56
111

PCL or
PLA
molar
massa
2300
5800
5900
11100
2300
4700
4800
11000

Mn a

Mn b

Đb

8400
14600
4300 5600 1.1
7800 6300 1.4
10900 9500 1.1
16100 10300 1.3
4300 5200 1.2
6700 9600 1.1
9800 10500 1.3
16000 13500 1.4

f valuea
0.80
0.82
0.47
0.26
0.46
0.31
0.47
0.30
0.51
0.31

PEG-PCL and PEG-PLA were synthesized using PEG monomethyl ether (2000 or
5000 g/mol) as the initiator and the block ratios were tuned by varying the equivalents of
-caprolactone or L-lactide to achieve PEG mass fractions (f) of approximately 0.5 and 0.3.
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Methanesulfonic acid was used as the polymerization catalyst for the synthesis of PEGPCL, while 1,5,7-triazabicyclo[4.4.0]dec-5-ene was used as the catalyst for PEG-PLA
synthesis.30, 31 A 1:1 ratio of catalyst:initiator was used in each case. Characterization of
the diblock copolymers was performed using 1H nuclear magnetic resonance (NMR)
spectroscopy (Figures A.3-A.10) and size exclusion chromatography (SEC) relative to
polystyrene standards (Figures A.11-A.14) and the results are summarized in Table 2.1.
Typical signals of PEG, PCL and PLA components were utilized to calculate the molar
ratios of polymerized monomers to PEG and thus the number average molecular weight
(Mn). The Mn and molar mass dispersities (Đ) were also measured by SEC. The f values
were calculated from the NMR data, as this should provide the most accurate assessment
of the block ratios. The values indicated for the poloxamers were taken from their
respective specification sheets. Overall, the measured Mn values, particularly from NMR
spectroscopy, and f values were in good agreement with the target structures.

2.3.3

Polymer Self-Assembly and ErNP Encapsulation

First, the self-assembly of the block copolymers without ErNPs was investigated. The
copolymers were dissolved in THF then this solution was added to water with stirring.
After removal of THF by dialysis, the resulting nanoassemblies were characterized by DLS
and TEM. The Z-average diameters measured by DLS ranged from 11 to 55 nm (Table 2.2,
Figure A.15), consistent with self-assembly into micelles and TEM images confirmed that
solid spherical particles were formed (Figure A.16). The PDIs ranged from 0.1 to 0.6,
suggesting that some copolymers assembled into nanoparticles with a narrow size
distribution (PDI < 0.3), whereas others exhibited a large distribution of sizes (PDI > 0.3).
In general, the TEM results were in good agreement with the volume distributions obtained
from DLS, except for both poloxamers (PEG76-PPG22-PEG76 and PEG137-PPG34-PEG137).
For these poloxamers, the volume distribution in DLS suggested the presence of small
scatterers that could be unassembled copolymers in solution, whereas the corresponding
TEM images showed larger nanoparticles that could result from aggregation during the
drying process.
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Table 2.2 Z-average diameters and PDIs obtained using DLS for the self-assembly of block
copolymers without ErNP. Each assembly was prepared and measured in triplicate and the
error measurements correspond to the standard deviations on these batches.
Polymer

Z-average diameter (nm)

PDI

PEG76-PPG22-PEG76

11 ± 2

0.6 ± 0.3

PEG137-PPG34-PEG137

17 ± 3

1.0 ± 0.4

PEG45-PCL20

20 ± 1

0.2 ± 0.1

PEG45-PCL51

17 ± 2

0.1 ± 0.1

PEG114-PCL51

18 ± 4

0.1 ± 0.1

PEG114-PCL97

31 ± 4

0.2 ± 0.1

PEG45-PLA25

26 ± 11

0.5 ± 0.2

PEG45-PLA52

29 ± 8

0.4 ± 0.1

PEG114-PLA122

31 ± 10

0.4 ± 0.2

PEG114-PLA53

55 ± 8

0.2 ± 0.1

Having confirmed the self-assembly behavior of the amphiphilic block copolymers alone,
ErNPs were then added. Both the copolymer and ErNP were dissolved in THF and then
nanoprecipitated into water to form suspensions of erbium-containing assemblies. The
mass ratio of polymer:ErNP was 4:1. THF was removed by dialysis, then the suspensions
were passed through a 0.45 m filter. This filtration served to remove any ErNP that had
not been encapsulated and consequently aggregated, as well as polymer-ErNP assemblies
that were too large and would be preferentially cleared from the blood by the mononuclear
phagocytic system (MPS).42, 43 The resulting assemblies were characterized by DLS and
TEM (Figure 2.4, Table 2.3). The TEM images showed individual ErNP or groups of ErNP
across the grid, unlike the oleate-coated ones in Figure 2.2b, which displayed no specific
organization or aggregation. This suggests the encapsulation of the ErNP within the
amphiphilic block copolymers. It should be noted that the polymers were indiscernible in
the TEM images because of the high contrast from the ErNP. The Z-average diameters that
were measured by DLS ranged from 53 to 183 nm. This also supported the encapsulation
of ErNP within the amphiphilic block copolymers, as these diameters were larger than
those of the polymer-only micelles.
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When PEG114-PLA122 or any of the PEG-PCL diblock copolymers were used to form the
assemblies, moderate PDIs (between 0.2 and 0.3) were observed. On the other hand, when
using either poloxamers or the other PEG-PLA diblock copolymers good PDIs (< 0.2) were
obtained. Because the contrast agent was simply required to remain in circulation (i.e. no
tissue-targeting was required), obtaining low PDIs was not of utmost importance; meeting
the size requirements that would allow evasion of immediate renal clearance and
preferential uptake by the MPS was sufficient.

Table 2.3 Characterization data for the polymer-encapsulated ErNP obtained from DLS
and ICP-MS both as initially prepared and after lyophilization followed by resuspension in
saline. The polymer:ErNP mass ratios were 4:1 unless otherwise indicated. Each assembly
was prepared and measured in triplicate and the error measurements correspond to the
standard deviations on these batches. aDetermined by DLS; bDetermined by ICP-MS where
780 g/L would correspond to encapsulation of 100% of the Er added during selfassembly.
In water following initial
Post-lyophilization and
preparationa
resuspension in salinea
Polymer
Z-average
Z-average
PDI
PDI
(nm)
(nm)
PEG76-PPG22-PEG76
174 ± 4
0.1 ± 0.1
294 ± 34
0.2 ± 0.1
PEG137-PPG34-PEG137 176 ± 6
0.1 ± 0.1
212 ± 2
0.2 ± 0.1
PEG45-PCL20
98 ± 10
0.3 ± 0.1
2145 ± 179
0.2 ± 0.1
PEG45-PCL51
82 ± 2
0.3 ± 0.1
3204 ± 416
0.2 ± 0.1
PEG114-PCL51
53 ± 5
0.3 ± 0.1
1057 ± 32
0.6 ± 0.1
PEG114-PCL97
84 ± 1
0.2 ± 0.1
2861 ± 9
0.4 ± 0.5
PEG45-PLA25
165 ± 2
0.1 ± 0.1
192 ± 4
0.5 ± 0.1
PEG45-PLA52
151 ± 2
0.2 ± 0.1
1597 ± 83
0.4 ± 0.1
PEG114-PLA122
130 ± 2
0.2 ± 0.1
301 ± 13
0.4 ± 0.1
PEG114-PLA53
154 ± 2
0.1 ± 0.1
134 ± 1
0.2 ± 0.1
PEG114-PLA53 (2:1)
180 ± 3
0.2 ± 0.1
180 ± 6
0.1 ± 0.1
PEG114-PLA53 (1:1)
179 ± 4
0.2 ± 0.1
171 ± 3
0.2 ± 0.1
PEG114-PLA53 (0.5:1) 183 ± 3
0.1 ± 0.1
185 ± 5
0.2 ± 0.1

Erbium
content
(g/L)b
62 ± 6
232 ± 1
377 ± 25
506 ± 3
596 ± 21
732 ± 22
407 ± 2
149 ± 1
339 ± 4
599 ± 3
583 ± 28
607 ± 16
533 ± 32
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Figure 2.4 DLS volume (%) diameter distributions and the corresponding TEM images of
polymer-encapsulated ErNP using a) PEG76-PPG22-PEG76, b) PEG137-PPG34-PEG137, c)
PEG45-PCL20, d) PEG45-PCL51, e) PEG114-PCL51, f) PEG114-PCL97, g) PEG45-PLA25, h)
PEG45-PLA52, i) PEG114-PLA53, and j) PEG114-PLA122.
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2.3.4

Redispersion and Characterization of the
Polymer-Encapsulated ErNP

Lyophilized

Because the polymer-encapsulated ErNP were prepared by nanoprecipitation at low
concentrations in water, the sample had to be lyophilized then redispersed at higher
concentrations. The ability to lyophilize and resuspend the assemblies is also advantageous
for their long-term storage. Dried samples were redispersed in 0.9% saline, which is
isotonic with blood, and the Z-average diameters of the assemblies were measured by DLS
(Table 2.3). No filtration was performed after redispersion. In addition, because colloidal
stability of the contrast agent in its administration medium is required, the Z-average
diameters of the redispersed ErNP-loaded assemblies were also observed by DLS over 60
minutes.
Relative to the pre-lyophilized diameters, minimal changes occurred for the PEG137-PPG34PEG137, PEG45-PLA25, and PEG114-PLA53 assemblies, while the remainder redispersed in
saline at much larger hydrodynamic diameters, suggesting that they were aggregated. For
example, the PEG76-PPG22-PEG76 assemblies, which initially had a Z-average
hydrodynamic diameter of 174 ± 4 nm had a diameter of 294 ± 34 nm after redispersion in
saline, while the PEG137-PPG34-PEG137 assemblies, which were initially 176 ± 6 nm, were
redispersed in saline at 212 ± 2 nm (Figure A.17). Given the very similar f values for these
polymers, the larger PEG block is likely capable or better stabilizing the particles. All PEGPCL assemblies redispersed in saline as micrometer-sized particles, which was
undesirable, as these particles would be rapidly cleared by the MPS (Figure A.18). The
colloidal instabilities of PEG-PCL assemblies have been reported before, which makes
them undesirable for use under normal physiological conditions. The PEG45-PLA52
assemblies also redispersed as microparticles and PEG114-PLA122 assemblies redispersed
at an increased Z-average diameter of 301  13 nm compared to an initial diameter of
130  2 nm (Figure A.19). Both of these copolymers had low f values of ~0.3, which may
contribute to their poor stability to redispersion. However, PEG45-PLA25 and PEG114PLA53 assemblies retained Z-average diameters of 192 ± 4 and 134 ± 1 nm after
redispersion in saline, similar to their initial diameters of 165 ± 2 and 154 ± 2 nm. Both
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remained colloidally stable for up to 60 minutes. This stability may result from their
increased f values of ~0.5.
ICP-MS was used to quantify the concentration of aqua regia-digested erbium that was
encapsulated by each system (Table 2.3). These measurements were performed on the
initially prepared samples after their filtration. If all of the added erbium had remained
dispersed in assemblies less than 0.45 m in diameter, the expected erbium concentration
of the suspensions would have been 780 µg/L. The highest erbium content was observed
for PEG114-PCL97 at 732 ± 22 µg/L. The second highest concentration was obtained with
PEG114-PLA53 at 599 ± 3 µg/L, then PEG114-PCL51 at 596 ± 21 µg/L. However, out of the
assemblies formed by these block copolymers, only PEG114-PLA53 assemblies could be
redispersed without a substantial increase in Z-average diameter in saline. The other block
copolymers that allowed size consistency had lower erbium content, with PEG137-PPG34PEG137 at 232 ± 1 ug/L and PEG45-PLA25 at 407 ± 2 µg/L. Decreased erbium content
resulted from the filtration of unencapsulated hydrophobic ErNP that aggregated in water
or ErNP in assemblies larger than 0.45 m in diameter. Based on this analysis, further
studies were performed with PEG114-PLA53 as it was able to form stable assemblies with
high erbium content.

2.3.5

Characterization of the Assemblies Formed with PEG114PLA53

The polymer content of the contrast agent does not contribute to the attenuation of x-rays
and hence will not contribute to higher contrast. It does however contribute to the total
mass of the material in solution, and increases viscosity, thereby making administration of
the suspension difficult. Thus, it would be desirable to decrease the polymer:ErNP ratio in
the assemblies. However, decreasing the polymer content of the assemblies has one
drawback, which is the potential decrease of their stealthiness and immune system
evasion.36 To investigate the possibility of lowering the polymer content of the contrast
agent while retaining stability, assemblies were formed with lower PEG114-PLA53:ErNP
mass ratios (from 4:1 to 2:1, 1:1 and 0.5:1). Their colloidal stabilities at 37 °C in saline
and in a mouse serum mimic were studied by DLS (Figure 2.5). The serum mimic
contained bovine serum albumin and ions at concentrations that are similar to mouse blood.
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The proteins can potentially contribute to polymer shedding, and thereby to nanoparticle
aggregation in vitro. In the blood pool of the animal in vivo, polymer shedding leads to the
detection by the immune system and clearance of the nanoparticles from the blood via the
liver.35, 36 In the DLS analysis, the proteins generated insignificant scattering that did not
interfere with the analysis of the assemblies (Figure A.20-A.21). The Z-average diameters
for the initially prepared assemblies ranged from 121-185 nm and did not vary significantly
over a period of 60 minutes in saline or in the mouse blood mimic, indicating that each
formulation was sufficiently stable.

Figure 2.5 Time-course DLS results at 37 C for PEG114-PLA53-encapsulated ErNP postlyophilization after redispersion in a) saline and b) mouse serum mimic.
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TEM imaging of the assemblies and analyses of their erbium content were also performed.
Denser ErNP cores were observed when the polymer:ErNP ratio was reduced (Figure 2.6).
Thus, decreasing the availability of polymers favored higher ErNP loading per assembly.
ICP-MS results revealed similar erbium content in the suspensions for all of the mass ratios.
Given this, and their colloidal stability in vitro, all the formulations should demonstrate
similar contrast enhancement values over time once concentrated and administered to the
blood pool. However, the concentrated solutions formed with polymer:ErNP mass ratios
of 4:1 and 2:1 had high viscosities that made the solutions too challenging to administer
in vivo though the 30 G needles. Hence, for subsequent studies, the assemblies containing
PEG114-PLA53:ErNP mass ratios of 1:1 and 0.5:1 were used. Using pyrene as a fluorescent
probe,44 the critical aggregation concentrations (CACs) for these 1:1 and 0.5:1
formulations were measured and compared to that of PEG114-PLA53 assemblies without
ErNP. We found that the CAC of the block copolymer alone was 26 mg/L, whereas those
of the 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations were 96 mg/L and 117 mg/L
respectively (Figures A.22-A.24). Thus, it is evident that the loading of ErNP destabilizes
the assemblies to some extent. Nevertheless, these CAC values are much lower than the
concentrations at which they would be administered, even after dilution into the blood pool.

Figure 2.6 TEM images of the PEG114-PLA53-encapsulated ErNP using polymer:ErNP
mass ratios of a) 4:1, b) 2:1, c) 1:1, d) 0.5:1.
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2.3.6

Erbium Content in ErNP Determined Via Micro-CT

While ICP-MS was used to detect erbium content before lyophilization, micro-CT was
used to confirm the erbium content of the redispersed and high concentration versions of
the contrast agents. A linear relationship between an element’s concentration and its
attenuation of x-rays exists and does not depend on the specific chemical form of the
element. This quantitative property of micro-CT contrast is one of its advantages as an
imaging modality. Calibration standards containing erbium chloride dissolved in saline at
concentrations of 0, 5, 10, 20 and 100 mg/mL of erbium were scanned. Using linear
regression of the measured CT numbers of the standards (Figure A.25), it was determined
that 40 mg of the lyophilized 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations dispersed in
0.2 mL of saline resulted in contrast element concentrations of 48 and 74 mg/mL of erbium
respectively. Therefore, 100 mg/mL is achieved when 42 mg of the 1:1 formulation and
27 mg of the 0.5:1 formulation is suspended in 0.1 mL of saline. Micro-CT scans of the
high concentration suspensions verified that 100 mg/mL of erbium was achieved when the
calculated amount of the agent was used (Figure A.26). While higher erbium loading can
be achieved with more concentrated solutions, we restricted the experiments to 100 mg/mL
in order to maintain low viscosities for intravenous injection in mice.

2.3.7

Toxicity of the Contrast Agent

The in vitro and in vivo toxicity of the contrast agent was evaluated prior to its intravenous
administration. Based on MTT assays, greater than 80% viability relative to controls was
observed for the 1:1 polymer to erbium mass ratio formulation up to concentrations of
0.5 mg/mL (Figure A.27). The 0.5:1 polymer to erbium formulation was even less toxic,
with greater than 80% viability up to 1 mg/mL, the highest concentration tested. We also
performed subcutaneous injections to study the materials in vivo. Subcutaneous tissue has
slow absorption and clearance rates of exogenous materials, which provides an opportunity
to study the reaction of tissues to the contrast agent over prolonged periods. Threedimensional micro-CT images were obtained in mice before the subcutaneous injection of
the 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations and two weeks after the administration
of the agent. Each scan took 16 seconds to acquire. Representative micro-CT images for
each of the contrast agent formulation injections are shown in Figure A.28. The images
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show that the contrast agent localized near the injection site for up to two weeks. Gross
examination of the subcutaneous tissue confirmed the presence of some contrast agent near
the injection site. No abnormalities were observed in either the subcutaneous tissue or the
dermis (Figure A.29).

Figure 2.7 Representative coronal micro-CT images showing the heart, liver, aorta, jugular
veins and bladder of mice that received contrast agent formulated at a) 1:1 and b) 0.5:1
PEG114-PLA53:ErNP mass ratios. All times are reported from the completion of the
contrast agent injection. In the 2 minute image in a), the external jugular veins (double
arrowheads) and the axillary veins (arrows) are clearly visible.

2.3.8

Distribution of the Contrast Agent In Vivo

Three-dimensional micro-CT images were obtained in mice before the intravenous
administration of both contrast agent formulations and at three time points following the
administration of the agent. Each scan took 16 seconds to acquire. Representative microCT images for each of the contrast agents are shown in Figure 2.7. After contrast agent
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administration, all the major vessels – particularly the external jugular and axillary veins
in Figure 2.7 – became clearly visible. For both formulations, there appeared to be no
change in contrast in the chambers of the heart for up to 60 minutes. The contrast in the
liver was seen as early as the 2-minute time point – demonstrated by the ability to
distinguish liver from surrounding soft tissue.
Quantitative analysis indicated an increase in blood pool CT number of over 250 HU
compared to pre-contrast values. The bladder was indistinguishable from pre-contrast
values, indicating that the agent was not cleared through the renal system, as expected of
materials that exceed the size of renal fenestrations.14 By the one-hour mark, the liver and
the spleen had increased up to 180 ± 15 HU and 278 ± 18 HU, respectively, for the 1:1
formulation, confirming the hypothesis that large nanoparticles are cleared through the
MPS.35, 36 In the myocardium, the CT number was just under 100 HU at all time points,
which was expected of soft tissue in the absence of contrast material. As expected, the 0.5:1
polymer:ErNP assemblies demonstrated lower stealth activity, due to the lower amount of
polymer used in the synthesis of the assembly, and were cleared from the blood more
rapidly as indicated by the decreased intensity of the blood pool in the micro-CT images.
Overall, this initial imaging study demonstrates that these new contrast agents can be
dispersed and injected into mice at a concentration sufficient to achieve vascular contrast
by micro-CT in vivo. Furthermore, the particles exhibited sufficient stealth properties to
circulate in the vasculature for at least 1 hour. This suggests the promise of these new
lanthanide-based agents for applications such as dual-energy imaging and spectral CT.

2.4

Conclusions

In this study, by systematically comparing a series of amphiphilic block copolymers
composed of different hydrophobic blocks and different PEG mass fractions, we identified
PEG114-PLA53 as an amphiphilic copolymer that can encapsulate oleate-coated NaErF4
nanoparticles. The PEG114-PLA53:ErNP assemblies redispersed into colloidally stable
particles in saline after lyophilization and remained in the blood pool in vivo for at least an
hour – a time period that well exceeds live animal micro-CT requirements. Importantly,
we were able to formulate the assemblies at a high concentration of 100 mg/mL of erbium
using PEG114-PLA53. At a delivered dose of 0.2 mL per mouse, this new contrast agent
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formulation resulted in the enhancement of blood pool in micro-CT images (at 80 kVp) by
approximately 250 HU (above a soft tissue baseline of 100 HU) for at least an hour
following contrast agent administration. This system should be readily adaptable for a
variety of lanthanides, as the metal can be easily substituted in the oleate-coated NaErF4
while retaining very similar properties, suggesting its promise as a new class of contrast
agents for micro-CT as well as other imaging modalities such as MRI and optical imaging,
in which lanthanides are utilized. Future studies will explore further the biodistribution and
toxicity profiles of these agents.
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Chapter 3

3

PEG-Modified Gadolinium Nanoparticles as Contrast
Agents for In Vivo Micro-CT

Vascular research is largely performed in rodents with the goal of developing treatments
for human disease. Micro-computed tomography (micro-CT) provides non-destructive
three-dimensional imaging that can be used to study the vasculature of rodents. However,
to distinguish vasculature from other soft tissues, long-circulating contrast agents are
required. In this study, we demonstrated that poly(ethylene glycol) (PEG)-coated
gadolinium nanoparticles can be used as a vascular contrast agent in micro-CT. The coated
particles could be lyophilized and then redispersed in an aqueous solution to achieve
100 mg/mL of gadolinium. After an intravenous injection of the contrast agent into mice,
micro-CT scans showed blood pool contrast enhancements of at least 200 HU for 30
minutes. Imaging and quantitative analysis of gadolinium in tissues showed the presence
of contrast agent in clearance organs including the liver and spleen and very low amounts
in other organs. In vitro cell culture experiments, subcutaneous injections, and analysis of
mouse body weight suggested that the agents exhibited low toxicity. Histological analysis
of tissues 5 days after injection of the contrast agent showed cytotoxicity in the spleen, but
no abnormalities were observed in the liver, lungs, kidneys, and bladder.

3.1 Introduction
Micro-computed tomography (micro-CT) provides a quantitative, non-destructive, fast and
cost-effective means of studying vascular disease in mouse models.1-9 In live mice, microCT can provide imaging resolution down to tens of micrometers within tens of minutes.
Because CT contrast is derived from the density-dependent attenuation of x rays, soft
tissues, which have similar densities, provide little differential contrast. Hence, x-ray
attenuating contrast agents are injected intravenously to distinguish the vasculature from
surrounding soft tissues during a micro-CT scan, enabling visualization and quantitative
tracking of blood vessels, including during studies of novel therapies for revascularization.10-12 For optimal utility in in vivo imaging, contrast agents must have a high
initial loading of a highly attenuating contrast element, circulate in the blood pool during
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the course of the micro-CT scan, and be cleared from the body after imaging to enable
longitudinal studies with repeated injections. Clinically used contrast agents comprise
small molecules that are cleared renally within seconds of intravenous administration;
while these contrast agents meet the requirements of human imaging where scan times are
short, in vivo micro-CT protocols require circulation times in the order of tens of
minutes.13-17
Advances in nanotechnology and polymer science have enabled the development of
commercially available agents that can evade immediate blood pool clearance and circulate
for prolonged periods in mice.16,

18

These agents are composed of nanoparticles with

diameters greater than 10 nm, thus avoiding clearance via the kidneys.5, 19-22 To further
evade clearance by the reticuloendothelial system (RES), carrier polymers that act as
shields from the in vivo milieu are used to coat the nanoparticles. This “core-shell” design
can also be used to deliver a high loading of contrast material in the core, making the design
important for micro-CT contrast agents, where contrast-agent concentrations of at least
100 mg/mL are typically required. Poly(ethylene glycol) (PEG) has been widely utilized
to coat nanoparticles to achieve long circulation times23, 24 because of its stealthy properties
with respect to the RES, high water solubility, low cytotoxicity, availability in different
lengths, and a terminal group that can be modified into functional groups to coat
nanoparticles.25, 26 For example, phospholipid-terminated PEG is used in Fenestra VC,
which encapsulates 50 mg/mL of iodine within lipid emulsions,8, 20, 27, 28 while 15 nm gold
nanoparticles are coated with thiol-terminated PEG in AuroVist, enabling contrast loading
of 200 mg/mL.29-31
As iodine is the most commonly utilized clinical contrast agent, many of the micro-CT
vascular agents rely on iodine’s attenuating properties. Apart from gold, which has higher
attenuation than iodine across the entire energy spectrum, metal-based agents such as
alkaline earth metals21 and transition metals,32 have been reported or commercialized.
Another class of metals that is ideally suited for micro-CT are the lanthanides (e.g.
gadolinium, erbium),33 which have k edges (38-64 keV)34 that coincide with the peaks of
the x-ray energy distributions typically used in high-resolution in vivo micro-CT scanners
(typically operating at below 100 kVp). The ideal position of the K-edges offers potential
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to increase contrast attenuation for single-energy micro-CT scans33 and, more importantly,
offers the opportunity to match the available x-ray spectrum and contrast agent in dualenergy micro-CT, which is used to distinguish contrast-enhanced vessels from inherently
high-attenuating tissues (e.g. bone, calcifications).35
Lanthanide agents designed for in vivo vascular micro-CT are not commercially available,
but studies are emerging demonstrating the utility of PEG-modified lanthanide
nanoparticles in microimaging.36-39 To prepare lanthanides that can be used in the in vivo
milieu in small animals, common methods include the use of clinically-available MRI
agents to formulate nanoparticles that evade rapid renal clearance, or the synthesis of
hydrophobic lanthanide nanoparticles encapsulated within a shell of phospholipid-polymer
conjugate molecules (i.e. liposomes or lipid nanoparticles). While suspending high
concentrations of lanthanides (i.e. at least 100 mg/mL) in an aqueous environments is
challenging, we have recently reported the successful synthesis of block copolymer
assembly encapsulations of erbium nanoparticles containing 100 mg/mL of erbium, and
demonstrated its utility as a vascular contrast agent when operating at 90 kVp.40 However,
accumulation of the agent within the RES organs resulted in limited animal viability two
days following in vivo contrast agents injection.
The purpose of this work was to synthesize a blood pool contrast agent with at least
100 mg/mL of lanthanide to be cleared by the RES. Instead of encapsulating multiple
nanoparticles in block copolymer assemblies that were greater than 100 nm in diameter,40
we hypothesized that an alternative approach of directly modifying the surface of
gadolinium nanoparticles (GdNP) with PEG, would result in smaller polymer-coated
nanoparticles, thereby assisting GdNP clearance from RES organs. We demonstrate that
such agents can be synthesized, lyophilized and then redispersed to achieve 100 mg/mL of
lanthanide in an injectable formulation. Our in vivo results show that the agents provide
contrast enhancement values of at least 200 HU in the blood pool for 30 minutes before
being processed in the liver and spleen. The agents were well tolerated with some
gadolinium retention in clearance organs observed 5 days after a high dose injection. To
our knowledge, this is the first report on the successful synthesis of colloidally stable
aqueous suspensions of gadolinium-based nanoparticles at 100 mg/mL that exhibit
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sufficient circulation times rendering them a suitable contrast agent for vascular imaging
by micro-CT.

3.2

Methods

The reagents and their commercial suppliers are available in Appendix B. Further details
on synthesis and characterization methods are also presented in Appendix B.

3.2.1
3.2.1.1

Contrast Agent Preparation and Physical Characterization
Synthesis of GdNP

Oleate (OA)-coated NaGdF4 (OA-GdNP) were synthesized by a previously reported
method.40 Phosphate-terminated PEG1000 (PPEG1000), PEG2000 (PPEG2000), and PEG5000
(PPEG5000), where the subscripts indicate PEG molar mass in g/mol, were also synthesized
as previously reported.41 Two versions of PPEG-coated GdNP were synthesized – one with
PPEG2000 only (PPEG2000-GdNP), and a formulation using both of PPEG5000 and PPEG1000
(PPEG5000-PPEG1000-GdNP). An overview of the PPEG-coating process is presented in
Figure 3.1. Specifically, GdNP (1.0 g) and PPEG2000 (1.0 g), each dissolved in 12.5 mL of
tetrahydrofuran (THF), were combined. Under magnetic stirring, 225 mL of deionized
water was added. After stirring for one hour, THF was evaporated and the nanoparticles
were purified by dialysis and sterile vacuum filtration (see Appendix B for details). The
purified GdNPs were lyophilized and stored at room temperature until they were
redispersed immediately prior to use. The same procedure was followed for PPEG5000PPEG1000-GdNP, except PPEG1000 (1.0 g) dissolved in THF (12.5 mL) was added and the
suspension was stirred for one hour before organic solvent evaporation.42
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Figure 3.1 The synthesis of a) PPEG2000-GdNP and b) PPEG5000-PPEG1000-GdNP. OA is
displaced by PPEG through ligand exchange, and the solution is purified by dialysis and
vacuum sterile filtration to eliminate OA and excess PPEG.

3.2.1.2

Physical Characterization

The hydrodynamic diameters of the GdNPs were measured by dynamic light scattering
(DLS) and were visualized by transmission electron microscopy (TEM). The gadolinium
concentration in the contrast agent was measured by inductively coupled plasma-mass
spectrometry (ICP-MS) and the results were used to determine the mass of dried contrast
agent required to achieve gadolinium concentrations of 100 mg/mL. Micro-CT imaging,
where image intensity varies linearly with concentration, was also used to verify the
contrast agent concentration (details in Appendix B).

3.2.1.3

Colloidal Stability

Saline, which is isotonic with blood, was selected as the solvent for the PPEG-GdNPs. The
mouse serum mimic was composed of pH 7.4 phosphate buffered saline, 0.5 µg/mL mouse
immunoglobulins, 10 mg/mL bovine serum albumin and 1 mg/mL sodium azide. Colloidal
stability in a mouse serum mimic in vitro served as an indicator of stability in the blood
in vivo. DLS size measurements were performed on the PPEG-GdNP redispersed at
4 mg/mL and the average sizes were observed for up to one hour.

3.2.1.4

Micro-CT scanning and image analysis

Scans were performed using a GE Locus Ultra micro-CT scanner (GE Healthcare, London
ON). Whole-body mouse images were acquired over 1000 views (360°, 16 ms per view)
at 80 kVp, 55 mA and reconstructed with an isotropic voxel spacing of 150 µm. Images
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were analyzed using MicroView (Parallax Innovations, London, ON) and CT attenuation
was reported in Hounsfield Units (HU). All HU values were measured over a volume of
450 (µm)3. The averaged CT attenuation in the bladder (pre-injection) was subtracted from
measured tissue attenuations, to report tissue contrast enhancement throughout this paper.

3.2.1.5

Contrast Agent Effect on Cell Viability

An in vitro cell viability assay was performed using C2C12 mouse myoblast cells, which
were incubated for 24 hours with contrast agent at concentrations from 0.063 to 1.0 mg/ml.
Following incubation cell viability was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay. Additional details are provided in Appendix B.

3.2.2
3.2.2.1

In Vivo Characterization
Animal Care and Handling

All animal studies were carried out in accordance with the regulations set out by the
University of Western Ontario’s Council on Animal Care (2018-001). The protocols that
were used are in agreement with the ARRIVE guidelines and were carried out in
accordance with the U.K. Animals Act, 1986 and associated guidelines. C57BL/6 male
mice (25-32 g) were anesthetized prior to contrast-agent injection and during micro-CT
scans with 3.5% isoflurane in O2 via a nose cone, reduced to 1.5% for maintenance.

3.2.2.2

Subcutaneous Tissue Reaction Test

The in vivo toxicity of the contrast agent was evaluated by injecting PPEG2000-GdNP and
PPEG5000-PPEG1000-GdNP (0.2 mL at 1 g/kg body weight, n=2 each formulation)
subcutaneously into the dorsal interscapular tissue. The animals were scanned immediately
after and two weeks post-injection. The animals were euthanized and dissected for gross
tissue observations. Additional details are provided in Appendix B.

3.2.2.3

Time-course contrast enhancement and biodistribution

The tail veins of seven mice were catheterized using PE-20 polyethylene tubing. PPEG2000GdNP was injected over a period of 3 minutes (0.2 mL at 1 g/kg body weight, n=4) while
PPEG5000-PPEG1000-GdNP (0.2 mL at 1 g/kg body weight, n=3) was injected over a period
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of 5 minutes. Micro-CT scans of the animals were obtained at 5, 10, 15, 30, and 60 minutes
post-injection, as well as 2 and 5 days after. The animals were weighed daily during the
experiments, until the subjects were euthanized on day 5. Major organs were processed for
gadolinium content measurements by ICP-MS and standard histological analyses.43

3.2.2.4

Statistical analysis

All values are reported as means ± standard deviations. A two-way repeated-measures
analysis of variance (ANOVA) was performed in Prism 8 (GraphPad Software Inc., San
Diego, CA, USA) for each formulation to evaluate differences between the contrast
enhancement in the vasculature, variations between ICP-MS-measured gadolinium content
of excised tissues on day 5, and to measure the effect of intravenous injections to mouse
weight. Results were considered statistically significant at p < 0.05.

3.3
3.3.1

Results
Physical Characterization

OA-GdNP and PPEG2000-GdNP had monomodal size distributions, with Z-average
diameters of 37 ± 1 nm and 50 ± 1 nm, respectively, both with polydispersity indices (PDI)
of 0.20 ± 0.01 (Fig. 3.2a). PPEG5000-PPEG1000-GdNP had a bimodal size distribution, with
a Z-average diameter of 118 ± 4 nm and a PDI of 0.30 ± 0.01. The particle sizes measured
by DLS were in good agreement with particle sizes observed in the TEM images (Fig. 3.2b,
c, d). After lyophilization and redispersion, PPEG5000-PPEG1000-GdNP had diameters of
202 ± 8 nm in saline and 226 ± 10 nm in a mouse serum mimic (Fig. 3.3). Colloidal stability
was retained for at least 2 hours with no substantial changes in Z-average diameters. Larger
diameters were observed upon redispersion for PPEG2000-GdNP (from 50 ± 1 nm to 354 ±
99 nm in saline and 201 ± 27 nm in a mouse serum mimic) and the diameters increased
over time in saline and the mouse serum mimic.
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Figure 3.2 Size distributions and microscopy images of the synthesized GdNPs. a) DLS
volume diameter distributions of OA-GdNP in cyclohexane, and PEG2000-GdNP and
PEG5000-PEG1000-GdNP in water. Representative TEM images of b) OA-GdNP,
c) PEG2000-GdNP and d) PEG5000-PEG1000-GdNP. The scale bar in b) applies to all TEM
images.
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Figure 3.3

Time-course

diameters

of

resuspended

PPEG2000-GdNP

and

PPEG5000-PPEG1000-GdNP at 37 °C. The contrast agents were redispersed in a) saline and
b) a mouse serum mimic for characterization.
ICP-MS analysis of the contrast agents indicated a gadolinium content of 30 ± 5% and 22
± 3% (w/w) for PPEG2000-GdNP and PPEG5000-PPEG1000-GdNP, respectively. Hence, to
achieve a gadolinium loading of 100 mg/mL in the contrast agent formulation, 66 ± 10 mg
of dried PPEG2000-GdNP or 90 ± 14 mg of PPEG5000-PPEG1000-GdNP need to be diluted
in 200 µL saline. The relation between CT contrast (HU) and gadolinium concentration
in mg/mL ([Gd]) was calculated to be HU = 31[Gd] – 3 (Figure B.1, Appendix B). Hence,
a contrast value of 3100 HU is anticipated with 100 mg/mL of gadolinium. The CT contrast
values obtained from PPEG2000-GdNP and PPEG5000-PPEG1000-GdNP were 3244 ± 57 HU
and 3195 ± 62 HU, respectively, corresponding to 105 ± 2 mg/mL and 103 ± 2 mg/mL of
gadolinium respectively.

3.3.2

In Vitro and In Vivo Characterization

In cell culture experiments with PPEG2000-GdNP and PPEG5000-PPEG1000-GdNP, greater
than 75% viability of C2C12 mouse myoblast cells was found for all gadolinium
concentrations evaluated, up to 1.0 mg/mL (Figure B.2, Appendix B); the GdNP are not
considered toxic according to the American Society for Testing and Materials.44 In
addition, micro-CT images of the dorsal interscapular region following subcutaneous
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injection (Figure B.3, Appendix B) showed contrast enhancement near the injection site
was nearly gone after two weeks. Full body gross examinations showed normal tissues.

Figure 3.4 Representative coronal micro-CT images showing the heart, liver, jugular veins,
and spleen of mice that received contrast agent formulated with a) PPEG2000-GdNP and b)
PPEG5000-PPEG1000-GdNP. All times were reported from the completion of the contrast
agent injection. In the 5-minute image in a), the blood in the chambers of the heart (circle),
liver (arrow) and the external jugular veins (double arrowheads) are clearly visible. In the
2- and 5-day images, the blood pool in the heart is no longer visible, the liver remains
visible, and the spleen (arrowheads) becomes visible. Adjacent anatomical slices were
shown for the images acquired within 60 minutes, while slices located 1 cm posterior were
shown in the 2- and 5-day images, to demonstrate the high contrast in the previously
indistinguishable spleen.
Representative time-course micro-CT images of mice injected with the GdNPs are shown
in Fig. 3.4. As expected, qualitative evaluation of the post-contrast images shows
opacification of the blood pool (vessels, chambers of the heart), which remained high over
the 60 minutes studied. Increased contrast was observed in the liver as early as 5 minutes,
as demonstrated by the ability to distinguish the liver from surrounding soft tissues;
contrast enhancement increased by the 2 day time point. Liver contrast decreased 5 days
after agent injection, accompanied by increased contrast in the spleen. The renal cortex was
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not distinguishable from surrounding tissues, confirming the evasion of renal clearance and
clearance via the RES. Quantitative evaluation of the contrast enhancement in the
vasculature and the RES organs is shown in Fig. 3.5. For PPEG2000-GdNP, an average
attenuation of 245 ± 32 HU was observed 5 minutes post-injection in the abdominal aorta,
while an attenuation of 278 ± 33 HU was observed for PPEG5000-PPEG1000-GdNP. Values
of 200 HU were observed in the blood pool for at least 30 minutes for both formulations.
No significant difference between the measured contrast enhancement of the vasculature
for up to 60 minutes, and no effect on attenuation due to PEG chain length were observed
(2-way ANOVA, p = 0.15 and 0.077, respectively).

Figure 3.5 Contrast enhancement in the organs of mice that were injected with a)
PPEG2000-GdNP and b) PPEG5000-PPEG1000-GdNP displayed similar trends over time,
where decreased attenuation in the vasculature was accompanied by increased attenuation
in the liver after day 3 (Fig. 3.6). There were no signiﬁcant differences between daily mass
measurements (p = 0.30).
The mice were lethargic one day after injection; normal behavior resumed on the second
day. The average mass of the injected animals decreased one day after agent injection for
both formulations and stopped decreasing
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Figure 3.6 Effect of the contrast-agent injection procedure on subject mass.
Based on post-mortem ICP-MS analyses of the tissues, low gadolinium concentrations
were found in the blood, while high gadolinium concentrations were observed in the liver
and spleen, as expected (Table 3.1). The livers and spleens excised from PPEG5000PPEG1000-GdNP-injected mice were visibly larger than the organs of mice that were
injected with PPEG2000-GdNP. While contrast values do not depend on the size or mass of
the organ, the total gadolinium contents of the organs were greater for PPEG5000-PPEG1000GdNP than PPEG2000-GdNP due to organ mass differences (96 ± 22 µg vs. 58 ± 14 µg for
the liver, and 68 ± 19 µg vs. 46 ± 11 µg for the spleen, respectively). In the heart, kidneys
and the bladder, gadolinium levels were below detection limits, but trace gadolinium was
measured in the lungs of mice injected with PPEG5000-PPEG1000-GdNP.
The calibration between CT contrast and gadolinium concentration (Figure B.1, Appendix
B) confirmed the agreement between HU values (Figure 3.5) and the ICP-MS results.
The HU values in the liver were calculated to be 298 ± 66 HU and 345 ± 108 HU for
PPEG2000-GdNP and PPEG5000-PPEG1000-GdNP, respectively, and were 387 ± 83 HU and
669 ± 78 HU in the spleen. The trace amounts of gadolinium found in the lungs by ICPMS were far lower than the noise and too low to be detected in the CT images. Significant
differences in the gadolinium content values between formulations were observed for the
liver (p = 0.0006) and the spleen (p < 0.0001). Of the injected gadolinium, a total of 5.6 ±
1.0 % and 12.4 ± 2.1 % remained in the evaluated organs for PPEG2000-GdNP and
PPEG5000-PPEG1000-GdNP, respectively.

76

Table 3.1 Gadolinium content of mouse blood and clearance organs determined by ICPMS. aReported w/w% were rounded up.

Tissue
Blooda
Lungs
Brain
Liver
Spleen

PPEG2000-GdNP
w/w % of
ppm
injected
gadolinium
1 ± 31
0.1 ± 0.2
0
0
0
0
9322 ± 2060
2.7 ± 0.6
12101 ± 2570
2.8 ± 0.6

PPEG5000-PPEG1000-GdNP
w/w % of
ppm
injected
gadolinium
5 ± 88
0.1 ± 0.8
52 ± 92
0.1 ± 0.1
0
0
10780 ± 3350
5.2 ± 1.6
20833 ± 2420
7.0 ± 0.8

Figure 3.7 Representative histology images for control and injected mice taken from tissues
after 5 days of injection. Liver tissues appear normal, while the spleen tissues of the
injected mice indicate basophilic nuclear contents in the cytoplasm and lower nuclear
densities than the control tissue.
Histological analysis revealed no differences between control and injected mouse liver
(Fig. 3.7), lungs, heart, kidneys and bladder (Figure B.4, Appendix B). In spleen tissues,
sections from the injected mice demonstrate the presence of basophilic nuclear contents in
the cytoplasm and a lower density of nuclei than observed in the control spleen section.
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3.4

Discussion

We successfully prepared a long-circulating Gd-nanoparticle-based vascular micro-CT
contrast agent. The nanoparticles can be freeze-dried and redispersed into a contrast agent
suspension that is colloidally stable and contains 100 mg/mL of gadolinium, which is
difficult to achieve in an aqueous solution. Whole-body CT images demonstrate sufficient
vascular enhancement (> 200 HU) over the time period required for scanning, and along
with histology and post mortem ICP-MS, confirm RES clearance of both agents. We report
the condition of the RES organs days after a high-dose intravenous injection of lanthanide
nanoparticles, which has rarely been reported previously. Our results are consistent with a
comprehensive study that demonstrated the performance and in vivo fate of alkaline-earth
metal and iodinated nanoparticles when used as vascular contrast agents for micro-CT.45
Our agent provides comparable vascular contrast and similar clearance pathways as
alkaline-earth metal nanoparticles, including their localization in RES organs postcirculation.
We selected PPEG2000 and PPEG5000 for this study since these are two of the most
commonly used PEG chain lengths in long circulating nanoparticles.46, 47 While the original
goal was to compare the performance of PPEG2000-GdNP and PPEG5000-GdNP, our
preliminary studies showed that PPEG5000-GdNP could not be redispersed adequately in
aqueous solution. It was suspected that exchange of PPEG5000 chains onto the GdNP was
more difficult than for PPEG2000, thus leaving some of the GdNP surface exposed. In
attempts to improve the coverage of the GdNP surface, excess PPEG5000 of up to five times
the mass of the GdNP was used when preparing PPEG5000-GdNP. However, the
nanoparticles could still not be entirely redispersed in water. Backfilling with a shorter
PEG chain length was adopted, which previous studies have demonstrated to reduce
interactions between nanoparticles and plasma proteins.42 To backfill, PPEG1000 was
selected as this PEG length that was not expected to interfere with the performance of
PPEG5000 in repelling plasma proteins. The lyophilized PPEG5000-PPEG1000-GdNP
redispersed without difficulty in saline and the mouse serum mimic to form particles with
average diameters that were no more than twice the pre-lyophilization diameters.
PPEG2000-GdNP redispersed at about 7-fold higher diameter than pre-lyophilization.

78

The PPEG5000-PPEG1000-GdNP formulation was observed (qualitatively) to have a higher
viscosity than PPEG2000-GdNP at concentrations of 100 mg/mL of gadolinium. This
resulted in longer injection times for PPEG5000-PPEG1000-GdNP, requiring 5-minute
injections versus the 3-minute injections when using PPEG2000-GdNP. We attribute the
higher viscosity of PPEG5000-PPEG1000-GdNP to the higher mass of polymer-coated
particles used to achieve 100 mg/mL of gadolinium in this contrast agent, since the
viscosity of a suspension containing solid spherical particles increases when a larger
volume of the solution is occupied by the particles/polymer.48 The longer PPEG5000 chains
on the particle surface may also contribute to higher viscosity compared to PPEG2000.
Nonetheless, similar contrast enhancement of the vasculature (above 200 HU) was
achieved for 30 minutes after injection for both formulations, with no significant change
in time-course attenuation for up to 60 minutes. The similarity in in vivo performance of
the reported formulations was unexpected because PPEG2000-GdNP showed poorer
colloidal stability than PPEG5000-PPEG1000-GdNP in saline and in the mouse serum mimic.
The indistinguishable performance of the two formulations in vivo demonstrates that in
vitro tests cannot fully predict the in vivo behavior of nanoparticles in the vasculature. The
nanoparticles reported in this paper exhibited the same circulation times and blood pool
contrast enhancements as our previous formulation comprising NaErF4 nanoparticles
encapsulated in assemblies formed from PEG-poly(lactic acid) block copolymers,40 which
also had PEG surfaces. This current study and our previous paper are further testaments to
the capabilities of PEG in temporarily promoting stealth properties against the RES and in
providing its cargo with long circulation times in the vasculature, even at the high doses
required for micro-CT.
No CT scans were performed after the first 60 minutes on day one or the day after injections
to avoid complicating mouse health due to anesthesia.49 The injected mice were clearly
lethargic after being under anesthesia for 60 minutes, and this effect was still observed after
one day. Two days following initial injection, the mice were placed under anesthesia for 5
minutes, only to permit micro-CT imaging; the mice were more active before and after
imaging, and only needed a few minutes to recover from anesthesia. The daily mass
measurements display a similar trend that coincides with mouse activity, food and water
intake. While a limitation of this study is that no sham study was performed to differentiate
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between the effect of the agent and the anesthesia, isoflurane was found to increase mouse
latency in previous studies, and coincided with decreased animal weight for up to 2 days.50
Our results – micro-CT time course and post-mortem ICP-MS of relevant organs – clearly
demonstrate that the agent’s clearance pathway is through the RES. This clearance
mechanism was expected due to its physical properties and is similar to the clearance of
other agents incorporating metal nanoparticles.32, 36 Some gadolinium was detected by ICPMS in trace amounts in the blood, and in the lungs of PPEG5000-PPEG1000-GdNP-injected
mice; the trace values found in the lungs can be attributed to reversible transient
aggregation in capillary beds and has been previously observed for other intravenously
injected nanoparticles.51, 52 Because of concerns with free gadolinium being observed in
humans post small-molecule contrast injection,53,

54

we evaluated the gadolinium

concentration in the brain and confirmed that our GdNP did not cross the blood brain
barrier.
The ICP-MS results reported significantly higher gadolinium accumulation in the liver and
in the spleen from PPEG5000-PPEG1000-GdNP than PPEG2000-GdNP. This could be
attributed to a difference in morphology and grafting density of the PEG molecules in each
version of the contrast agent, hence affecting its biodistribution.55, 56 Considering greater
RES organ accumulation, higher viscosity, and heavier excised livers and spleens from
PPEG5000-PPEG1000-GdNP injections than from PPEG2000-GdNP, and no significant
difference in time-course contrast enhancements of the vasculature, an advantage can be
gained from using PPEG2000-GdNP instead of PPEG5000-PPEG1000-GdNP for in vivo microCT. This result was unexpected, because the nearly constant size of PPEG5000-PPEG1000GdNP from the in vitro colloidal studies predicted that it would outperform PPEG2000GdNP which was expected to aggregate in vivo as was observed in vitro. We suspect that
the aggregation of PPEG2000-GdNP may be transient and reversible allowing mobility and
reduced accumulation in RES organs in the dynamic environment in vivo.
Optical histology results showed that all tissues examined, except for the spleen, were
normal. Since eosin stains the acidophilic cytosol and extracellular matrix, and
hematoxylin stains the basophilic nucleus, the spleen sections indicate the presence of
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nuclear content in the cytosol and extracellular matrix, and lower nuclear density,
suggesting the need for further investigations. In this study, mice were euthanized after the
5-day time point because after that time point it is difficult to gauge if well-being is a result
of the contrast agent or other factors. The contrast agent formulation that we report in this
paper presents an improvement from our previously reported nanoparticle assembly
formulation, where most mice died after 2 days.
Our surface-modified GdNP can be used to visualize the vasculature of live mice using
micro-CT for up to 60 minutes. The contrast agent that we synthesized is an improvement
from our previous formulation, since the injected mice survived for up to 5 days. Hence,
the agent can potentially be injected up to two times to visualize and quantitatively track
blood vessel development by micro-CT within 5 days. While further studies are required
to enable the contrast agent’s utility in long-term studies, our results show that switching
from diblock polymer coated nanoparticle assemblies to grafting PEG directly on the
surface – preferably with PEG2000 – facilitated the exit of nanoparticles from the liver.

3.5

Conclusions

We synthesized long-circulating contrast agents composed of PEG-modified GdNP that
can be suspended at 100 mg/mL of gadolinium and can be used to visualize the vasculature
of live mice using micro-CT for up to 60 minutes. The alternative approach of modifying
the surface of the nanoparticles with PEG in lieu of polymer-coated nanoparticle
assemblies presents a step in the right direction towards making micro-CT contrast agents
available for longitudinal vascular research.
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Chapter 4

4

In Vivo Dual Energy Micro-Computed Tomography
Imaging of the Mouse Vasculature Using Gadolinium
Nanoparticles as Contrast Agent

4.1 Introduction
Micro-computed tomography (micro-CT) is widely used to study the vasculature in mouse
models of human disease.1-9 Micro-CT can provide quantitative, non-invasive, threedimensional and high-resolution images (i.e. tens of micrometers) of live mice within tens
of minutes. Since contrast in micro-CT depends on the inherent density of tissues, contrast
agents containing high-density elements are required to distinguish the vasculature from
surrounding soft tissues. However, discriminating the contrast-enhanced vasculature from
high-density tissues in the body, such as bone, can be challenging, especially for vessels
that are inside or near bone. To identify contrast-enhanced vessels from bone, dual energy
(DE) micro-CT can be performed.
DE micro-CT can differentiate materials within a given volume, using a pair of images
acquired using different x-ray spectra.10-13 The benefit of DE imaging is that it takes
advantage of the sharp increase in attenuation of x-rays just above the K-edge of the
contrast agent.14 The K-edge is a unique signature that each element has, which
corresponds to the energy required to liberate an inner shell electron. By selecting a pair of
x-ray spectra that tunes in to the K-edge of the selected contrast element, the tissue
containing the agent can be distinguished from the rest of the image. For instance, DE CT
in humans relies on spectral separation for optimal use of iodine agents, where the low
energy spectra (80 kVp) tunes in for high iodine attenuation due to the K-edge at 33.2 keV,
and lower iodine attenuation when imaging with the high-energy spectra (140 kVp).15 A
large installed base of in vivo scanners operates between 30-90 kVp, which restricts
spectral separation capabilities, as a limited energy spectrum is available. Spectral shaping,
using added filtration, can be used to obtain high photon flux just below and just above the
K-edge. This is difficult to achieve when the contrast material has a K-edge around 30
keV, due to the limited photon flux generated at the energies. Therefore, a contrast element
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with a K-edge in the middle of the micro-CT x-ray spectrum (i.e. 50-60 kVp) would
provide enhanced opportunity to perform DE decomposition.13
Like in human imaging, commercially available pre-clinical contrast agents are
predominantly based on iodine, the K-edge of which is too low, making the generation of
a sufficient number of photons difficult below the K-edge. While there are commercially
available lead-based ex vivo agents, and more recently developed gold-based formulations
for in vivo imaging of small animals,10, 16 obtaining a sufficient photon flux above the Kedge of lead (88 keV) and gold (80.7 keV) requires high x-ray tube potential. With respect
to x-ray attenuation properties, the ideal class of metals for DE micro CT are the
lanthanides, which have K-edges between 38-64 keV – a range that coincides with the
average energy of x-rays that most micro-CT scanners produce.17 The use of lanthanidebased contrast agents for DE micro-CT has been recently demonstrated ex vivo by Tse et
al18 who used a vascular perfusion contrast agent comprised of homogeneously
incorporated erbium nanoparticles (K-edge of 57.5 keV)13 in combination with spectral
shaping. This study demonstrated the successful implementation of optimized DE CT that
can be used with any pre-clinical cone-beam micro-CT scanner, resulting in highly accurate
decompositions of perfused rat hindlimbs into quantitative soft tissue, bone, and perfused
vasculature volumes.
We have developed an in vivo analogue of a nanoparticle-based long-circulating contrast
agent that can load 100 mg/mL of lanthanides. Our repeatable technique results in a
contrast agent that remains in the vasculature for at least an hour, composed of NaErF4
nanoparticles encapsulated in assemblies formed from PEG-poly(lactic acid) (PEG-PLA)
block copolymers.19 Hence, the purpose of this work was to demonstrate the feasibility of
an in vivo DE CT technique that can decompose the mouse volume into soft tissue, bone
and lanthanide-contrast-containing vessels. This study uses gadolinium as a model
lanthanide (K-edge of 50.2 keV) and used the method from our previously published paper
(Chapter 2) to synthesize the in vivo contrast agent.19 To our knowledge, this is the first
demonstration of an in vivo DE CT technique using a lanthanide-based contrast agent,
which can be used with any pre-clinical, gantry-based micro-CT scanner.
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4.2 Materials and Methods
4.2.1

Spectral Modeling

X-ray spectra were modelled using the SPEKTR 3.0,20 computational tool for x-ray
spectral simulation within MATLAB (R2018b, MathWorks Inc, Natick, MA). CT scannerspecific parameters were modelled to simulate the GE speCZT micro-CT (GE HealthCare,
London, ON), including a target angle of 15°, source-to-isocenter distance of 22.59 cm,
additional anode inherent filtration equivalent to 1.0 mm Al (Dunlee, DU 404), and 2 cm
Lexan.
The maximum tube potential of 90 kVp was selected, and x-ray filters composed of copper
and gadolinium were used to produce the low- and high-energy x rays. SPEKTR 3.0 was
used to determine the thickness of each filter that would result in mean energies below and
above the K-edge, while generating virtually similar photon flux.

4.2.2

X-ray Filter Fabrication and Automation

X-ray filters in the form of cylindrical shells that surround the scan bed and fit within the
scanner bore were created (Figure 4.1).13 The filter acts through a combination of pre- and
post-object filtration, equivalent to a total attenuation of a pre-object filter of double the
shell’s thickness.
Two filters were fabricated – a copper filter for the high-energy spectrum and a gadolinium
filter for the low-energy spectrum. The copper filter is comprised of three 80 µm copper
sheets wrapped around an acrylic shell, providing a total path length of 480 µm. Since
gadolinium foil is not available, a novel approach to filter design was utilized. Specifically,
a cylindrical shell containing a 2.2 mm hollow cavity was printed via the fused deposition
of polyamide. The cavity was filled with a 4% w/v gadolinium in distilled water
(i.e. 95 mg of gadolinium trichloride hexahydrate per mL of water), equivalent to a total
pathlength of 0.18 mm of gadolinium. The liquid filter is attached to an acrylic shell around
which the copper filter is wrapped. The dimensions of the acrylic support tube were
dictated by scanner dimensions and scan field of view; in this case the filters were 5 cm in
height and 8 cm inner diameter. The filters are controlled by an exchange mechanism that
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automatically switches the x-ray filters within the scanner bore in between frames,
emulating the acquisition of interleaved low- and high-energy scans. This mechanism is a
modification of the that described by Tse et al.18 where the motor and motor driver were
replaced to enable rapid filter switching that can be performed at every projection angle. A
custom 3D printed mouse bed - featuring a bridge over the bed - was designed to facilitate
reproducible filter switching over the subject (Figure 4.1).

Figure 4.1 DE micro-CT setup for a gantry-based micro-CT. a) Custom 3D-printed mouse
bed designed with a bridge over the bed (arrow in a) enables the custom filters to slide
reproducibly over the subject. b) The filter switching mechanism, with the filter in the highenergy state.

4.2.3

Image Co-Registration

While the low and high-energy images were acquired in an interleaved fashion (see below),
the potential for misalignment of the final volumes was mitigated by introducing fiducial
markers beads around the edges of the custom-built bed. The method described by Tse et
al.18 was used.

Briefly, polytetrafluoroethylene spheres (1.6 mm, Teflon™) were

embedded in a distributed pattern throughout 2-mm thick polystyrene foam sheets lining
the custom 3D-printed bed; Teflon™ was selected to facilitate marker segmentation. The
centroids of a minimum of eight beads were used to register the high- and low-energy
images with sub-voxel accuracy via rigid transformation. The original and registered low
energy images were subtracted from their respective high-energy image to verify the
success of the co-registration technique.
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4.2.4

Dual-Energy Micro-Computed Tomography

The DE acquisition and decomposition was first evaluated using a cylindrical acrylic
phantom (4 cm outside diameter) containing a bone-mimicking calibrator (SB3, Gamex
RMI, Middleton, USA), water, and 100 mg/mL of gadolinium in distilled water, prepared
by diluting 168 mg of gadolinium chloride per mL of water. The Animal Care Committee
of Western University Council for Animal Care approved all procedures. Male C57BL/6
mice (n=8, 25-30 g) were anesthetized initially using 3.5% of isoflurane in O2, followed
by maintenance at 1.5%. Polymer encapsulations of gadolinium nanoparticles optimized
for in vivo micro-CT imaging – specifically composed of sodium gadolinium tetrafluoride
nanoparticles within assemblies of poly(ethylene glycol)-poly(L-lactide) – were prepared
in powdered form as described in Chapter 2.19 The nanoparticles were added to 0.2 mL of
saline immediately before micro-CT scans at a concentration of 100 mg/mL of gadolinium,
then intravenously administered via tail vein catheterization.
DE images were obtained with the GE speCZT micro-CT scanner. The x-ray technique
was a two-phase electrocardiogram (ECG) gated scan acquired at 90 kVp, 32 mA, 4x4
binning (resulting in 100 μm isotropic voxel spacing), 220 projections over 192°, 4 frames
averaged per projection, and 16 ms per frame. To start the scan, the filter controller
positions the copper filter in the field of view and produces an ECG pulse that instructs the
scanner to acquire the first phase frames (i.e. high-energy images). The scanner sends a
signal to the filter controller after high-energy image acquisition, followed by the filter
controller placing the liquid gadolinium filter in the field of view. The controller produces
another ECG pulse that instructs the scanner to acquire the second phase frames
(i.e. low-energy images). The scanner sends a signal to the filter controller after low-energy
image acquisition, and the cycle is repeated for 220 projections. The entire DE scan was
acquired over 15 minutes.
The acquired frames were iteratively reconstructed using unregularized conjugate gradient
least-squares optimization in the RTK 1.3.0 toolkit.21 An in-house conjugate gradient leastsquares programming utility was used with optimized reconstruction parameters to
maintain adequate image quality (i.e. noise reduction and spatial resolution) in the 3D
reconstructions from a reduced number of views (220). Following reconstruction, the
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images were rescaled into Hounsfield units (HU) using vials of water and air within the
field of view.

4.2.5

Image Decomposition and Evaluation of Results

The decomposition of DE CT images was performed by matrix factorization, as previously
reported by Granton et al.11 and is described in detail in Appendix C. Briefly, the algorithm
uses six CT numbers, represented by the mean CT number of soft-tissue, bone, and
contrast-enhanced blood vessels in the low- and high-energy images. MicroView 2.6.0
(Parallax Innovations Inc., London, ON) was used to measure the mean CT number from
(300 μm)3 regions-of-interest (ROI) in the bladder (soft tissue), femoral cortical bone, and
abdominal aorta (gadolinium-enhanced vessel). The generated decomposed volumes
represent quantitative maps of each individual material, with voxel values
(0-10,000 arbitrary units) representing the volume fraction (0-100% respectively) or the
percent contribution of the decomposed material within each individual voxel, assuming
the sum of all three volume fractions equals 100%.
Quantitative evaluation on the accuracy of DE micro-CT decomposition was performed on
the phantom and each mouse by quantifying the number and distribution of misclassified
voxels within each decomposed volume. To quantify misclassified voxels, ROIs (300 µm
X 300 µm X 300 µm) in the bladder, femoral cortical bone, and abdominal aorta were
generated in each of the decomposed volumes, ensuring that the ROI coordinates were
identical between volumes. Mean bone, soft tissue, and contrasted vessel values were
recorded

for

each

mouse.

An

accurate

decomposition

would

have

been

10,000 arbitrary units or 100% for bladder in the soft tissue image, for femoral cortical
bone in the bone image, and for the abdominal aorta in the gadolinium-enhanced vessels
image. The same quantitative analysis was performed in the phantom image, except in
volumes within water, and in the bone and gadolinium calibrators. Statistical analysis was
performed using Prism 8 (GraphPad Software, San Diego, USA).
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4.3 Results
4.3.1

Spectral Modeling

The SPEKTR 3.0 simulated unfiltered 90 kVp spectrum and filtered low- and high-energy
spectra are shown in Figure 4.2. The unfiltered 90 kVp spectrum yields an average energy
of 43 keV; the copper and gadolinium filters shift the mean energy to 59 and 49 keV,
respectively. The flux ratio of the high- and low-energy x-rays was 1.02 when 3 cm of
cylindrical soft tissue is placed within the imaging field of view (0.91 without soft tissue).

Figure 4.2 Modelled spectral distributions of the unfiltered 90 kVp spectra, and with the
addition of the copper or liquid gadolinium filters to produce the low- and high-energy xrays for DE micro-CT.

4.3.2

Image Co-Registration

To verify the effectiveness of the image registration technique, the difference between
high-energy and low-energy images were examined. Representative slices from nonregistered and co-registered difference images are shown in Figure 4.3. In the absence of
image registration, the difference between the low - and high-energy image reveal obvious
tissue borders, predominantly surrounding the bone and the mouse body, which are
eliminated by co-registration. In the co-registered images, negative contrast is seen in bone,
which can be attributed to spectral differences.
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Figure 4.3 Representative a) coronal, b) sagittal, and c) axial slices from the difference
between non-registered (left) and co-registered (right) images.

4.3.3
4.3.3.1

Material Decomposition
In vitro Decomposition

Coronal slices from the material decomposition of an acrylic phantom containing water, a
bone calibrator and a gadolinium calibrator, as well as a representative high-energy image
are shown in Figure 4.4. The DE CT decomposition yielded accuracies of 99.43 ± 0.46 %,
97.47 ± 0.48 %, and 94.32 ± 1.56 % in the water, bone, and gadolinium volumes,
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respectively (Table 4.1), averaged from three (300 μm)3 ROIs within the same volume. All
material misclassifications are below 6%.

Figure 4.4 Coronal slices of the acrylic phantom containing water, bone, and gadolinium
calibrators. Material decomposition resulted in a) water, b) gadolinium, and c) bone
volumes. d) Representative slice from the high-energy image. The top scale bar represents
percentage compositions for decomposition images and bottom scale bar represents CT
contrast in the high-energy image.

Table 4.1 Quantitative assessment of in vitro DE decomposition. Percentages of correct
material classifications are underlined.
Percentage of
Material Classified
Water
Bone
Gadolinium

Decomposition Image
Water
Bone
Gadolinium
99.43 ± 0.46
0.04 ± 0.05
0.05 ± 0.03
0.24 ± 0.08
97.47 ± 0.48
2.38 ± 1.15
4.94 ± 0.05
2.73 ± 0.54
94.32 ± 1.56
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4.3.3.2

In vivo Decomposition

Dual energy micro-CT images were acquired in each of the eight mice, with an average
duration between contrast agent injection and start of scan of 51  20 minutes. Mousespecific CT numbers were collected from ROIs of the bladder, femoral cortical bone, and
the contrast-enhanced abdominal aorta, and are summarized in Table C.1. (Appendix C).
When implemented with the matrix factorization decomposition technique, quantitative
three-dimensional volumes of soft tissue, bone and gadolinium-enhanced vessels were
generated for all mice. Representative bone and gadolinium-enhanced vessels volume
images are shown in Figure 4.6 a and b, respectively. To further demonstrate the need for
co-registration, volume decomposition was demonstrated in a representative mouse, which
exhibited substantial misclassification of bone and soft tissue as gadolinium-enhanced
vessels near tissue borders (Figure C.1, Appendix C).
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Figure 4.5 Maximum intensity projections through a) the bone and b) gadoliniumenhanced vessels volumes demonstrate the quality of the decomposition. For comparison,
MIPs through the high c) and low d) energy volumes are also shown. The window and
level were set to optimize visualization of the vessels.

4.3.4

Quantification of Tissue Decomposition Results

The DE CT decomposition generated correct voxel classifications of 93.00 ± 8.53 %,
95.60 ± 3.52 %, and 83.39 ± 12.47 % for tissue, bone, and vessel volumes, respectively, as
quantified from eight mice. The corresponding graph of the percentage of correctly
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classified and misclassified voxels within each decomposed volume is illustrated in
Figure 4.7.

Figure 4.6 Tissue decomposition results averaged from all subjects. Misclassifications are
nearly absent for bone in the soft tissue image, and for soft tissue and blood vessels in the
bone image.
Examination of an oblique view of the left pelvic and hindlimb region of one of the mice
demonstrated the improved visualization of the branching vessels from the common iliac
artery and vein are identified in the gadolinium-enhanced vessels image (Figure 4.8); these
branches are measured to be at least 0.25 mm in diameter and are difficult to distinguish
from bone in the low-energy or high-energy images.
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Figure 4.7 Thick 1.5-cm oblique MIPs of the left pelvic and hindlimb region. The
decomposed a) bone and b) gadolinium-enhanced vessels volumes show additional vessels
(arrow) originating from the common iliac artery and vein (single arrowhead), apart from
the femoral artery and vein (double arrowheads). Smaller vessels are otherwise difficult to
identify in the c) low-energy or d) high-energy image. A tight window and level were used
to display c) and d) to favor the visibility of blood vessels.

4.4

Discussion

In this study, we have implemented an in vivo DE CT technique using an optimized
vascular contrast agent composed of polymer-encapsulated gadolinium nanoparticles, and
supplementary apparatus composed of custom x-ray filtration, a liquid filter, an automated

99

filter-exchange mechanism, and fiducial marker-based image co-registration to
successfully decompose images acquired from a pre-clinical gantry-based cone-beam
micro-CT scanner. To date, this is the first demonstration of DE micro-CT of the
vasculature of live mice using long-circulating gadolinium nanoparticles as contrast agent.
A constant tube potential of 90 kVp was selected, supplemented by custom filtration for
spectral separation, to permit the acquisition of interleaved scans, with the original intent
of avoiding the need for image co-registration. The tube potential was set to 90 kVp
because it is typically the maximum tube potential of a large number of high-resolution
in vivo micro-CT scanners most commonly utilized kVp to optimize image contrast and,
signal-to-noise-ratio, and x-ray tube cooling. The mean energy of the unfiltered spectrum
43 keV is close to the K-edge of gadolinium (50.2 keV), which was anticipated to require
the least filtration for optimal dual energy acquisition. Selecting a lower tube potential
would have resulted in a lower mean energy, necessitating greater filtration to obtain the
high-energy spectrum. Copper was selected to filter the high-energy spectrum because of
its low cost, accessibility at varying thicknesses, and its current use in CT and micro-CT.11,
13, 22, 23

While additional filtration can enhance spectral separation, the resulting diminished

photon flux will result in images with poor signal-to-noise ratio, again compromising
decomposition accuracy. To generate the low-energy spectrum, a gadolinium-based liquid
filter was used, by filling a cylindrical polyamide shell with gadolinium chloride diluted in
water, as it inherently attenuates photons above its K-edge. Implementing the use of a
liquid filter allows the user to customize the choice of filtration material and control over
the pathlength of the filter simply by changing the concentration of the gadolinium solution
utilized.
As previously mentioned, the initial goal was to acquire interleaved scans to eliminate the
need for image co-registration. However, the scanning table in the GE speCZT was not as
rigid as anticipated, demonstrated by the displacement observed between low-energy and
high-energy images, which is attributed to filter-position-specific sag introduced when the
copper filter was positioned over the mouse. The misregistration between the low- and
high-energy images is apparent in the difference images. Importantly, the fact that image
registration was successful suggests that the table sag introduced by the filter was
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reproducible between projection angles. While placing metal foils at the x-ray tube port,
prior to the sample, would remove the need for the external filter assembly, the addition of
a filter switching mechanism on the tube port may interfere with the gantry balance and
the normal operation of the scanner. Therefore, a cylindrical shell filter that surrounds the
scan bed yet fits within the scanner bore with an external filter switcher controller was
used. This approach to filtration avoids modifications to the scanner and is compatible with
gantry-based scanners. The cylindrical shell filters the x-rays before and after the object
being scanned, providing a total attenuation that is equivalent to a mounted filter of with
the same path length. Sub-voxel image co-registration of the volumes was enabled by
embedded Teflon™ marker beads. While this co-registration was successful in removing
filter-switcher-induced sag, were used as fiducial markers and were easily segmented.
Operator intervention was only required to select seed points for an automated centroid
calculation and co-registration.
Generally, CT numbers measured from “pure” calibrators or global values averaged from
all scanned subjects are used in DE CT decomposition algorithms. However, this study
used an in vivo vascular agent that introduces contrast to the blood pool that decreases over
time. While DE CT images were acquired and processed seamlessly and uniformly, the
main limitation in this study was the variability of the time required to set up the mouse
bed and cylindrical filter over the subject (varying from 20 to 90 minutes), due to contrast
agent injection occurring outside of the scanner. This is followed by filter positioning
within the field of view, which required a quick scan for position verification, often leading
to further delays due to repositioning. Hence, in this study, CT numbers specific to each
mouse subject were collected and used in the matrix factorization algorithm for DE CT
decomposition. More importantly, the delay between contrast agent injection and DE CT
scan acquisition resulted in lower enhancement in the vasculature compared to the expected
peak enhancement of approximately 250 HU.19
The quantitative assessment of DE CT decompositions resulted in at least 90 % accuracy,
with the exception of 15.87 ± 17.81 % soft tissue detection in the gadolinium-enhanced
vessels image. A substantial percentage of misclassified voxels were coincident with
scanned mouse subjects that had lower enhancement in the abdominal aorta. Since mouse-
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specific CT numbers were used in volume decomposition, misclassifications were not
anticipated. However, the difference between CT numbers that were used for detecting
gadolinium-enhanced vessels approached that of soft tissue for mice that had low vascular
contrast, resulting in an overlap between possible CT numbers for soft tissue and
gadolinium-enhanced vessels (hence, the misclassifications).
Decomposing bone from major arteries and veins was successfully demonstrated in the
pelvic region, where in the gadolinium-enhanced vessels image, the root or termination of
connecting vessels at least 0.25 mm in diameter were detected. Smaller vessels were
difficult to distinguish with the images composed of (100 μm)3 voxels in this study, due to
low vascular contrast and partial volume effects. While previous work has suggested that
DE CT may be partially resistant to partial volume effects,24, 25 as DE CT may still allow
for the detection and quantification of small vessels over varying spatial resolutions, higher
gadolinium concentrations are required than presented in this work. This is possible in
ex vivo perfusions where higher contrast agent concentrations can be achieved in the lumen
or through the technique presented in this study, except with higher vascular contrast
through reduced set up time and increased gadolinium loading in the contrast agent.
Our in vivo DE CT technique can be used to distinguish major vessels of live mice from
surrounding bone using a pre-clinical, gantry-based micro-CT scanner. The technique
presented allowed for the automatic decomposition of gadolinium agent-injected mice into
quantitative images of soft-tissue, bone, and gadolinium-enhanced vessels. This
decomposition was achieved by the interleaved acquisition of DE CT images, through
custom x-ray filtration and an automated filter exchange mechanism. Fiducial marker
beads enabled the co-registration of DE images, for volume decomposition by the matrix
factorization algorithm. In regions near bone, vessels at least 0.25 mm in diameter can be
identified and separated from the rest of the mouse volume. While further studies are
required to optimize subject setup and to investigate the ability of this technique to
overcome partial volume effects, our results demonstrate the feasibility of in vivo DE CT
of the mouse vasculature.
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4.5

Conclusions

We present an in vivo DE CT technique that can produce quantitative images of
decomposed soft tissue, bone, and vessel volumes that can identify major vessels from
surrounding bone, and can be used with any pre-clinical, gantry-based micro-CT scanner.
Our promising results show that vessels at least 0.25 mm in diameter can be distinguished
from bone, which can be improved by reducing set up time and increased in vivo vascular
contrast agent concentration. The presented technique can be used as a quantitative tool to
assess vessel densities in vascular research.
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Chapter 5

5

Conclusion and Future Directions

5.1 Summary of Thesis Results
Dual energy (DE) computed tomography (CT) has the capability to impact medicine and
preclinical research by providing quantitative information that can quantify vessel density,
detect nascent lesions, and identify perfusion restoration or inhomogeneities within tissues.
A library of instrumentation techniques and scan protocols have been developed for
DE CT, with the goal of acquiring a pair of images that reports the attenuation of a given
volume to two different x-ray distributions. While DE image acquisition has benefitted
from technical advancements in CT, the contrast agents that are used are still
predominantly composed of iodinated small molecules, which were first developed in the
1970s. Recent work has demonstrated that lanthanide-based contrast agents have optimized
properties for DE decomposition,1 specifically when using in vivo micro-CT scanners. By
adopting nanoparticle design strategies that were developed for therapeutics and disease
diagnosis, this thesis took advantage of technical advancements in nanotechnology and
polymer science to develop a long-circulating contrast agent containing lanthanides that
can be utilized for in vivo DE micro-CT of mouse vasculature.
In Chapter 2, erbium nanoparticles encapsulated within amphiphilic block copolymers –
either synthesized in customized lengths or purchased – were fabricated. The amphiphilic
block copolymers that were used contained poly(ethylene) glycol (PEG), which is a
polymer that is widely used in in vivo applications, and is known to introduce temporary
stealth properties to its cargo, enabling them to evade the immune system.2-4 By measuring
erbium concentrations by inductively-coupled plasma mass spectrometry and observing in
vitro colloidal stability via dynamic light scattering measurements of the hydrodynamic
diameters of the assemblies in water, saline and a mouse serum mimic, the most promising
copolymer was selected for further characterization. PEG-poly(lactic acid) assemblies
demonstrated in vitro colloidal stability for at least an hour and were able to concentrate a
high loading of 100 mg/mL of erbium for intravenous injections of mice. The injected
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subjects were imaged by micro-CT and CT contrast enhancements of over 250 HU were
observed in the vasculature for at least an hour, which well exceeds in vivo micro-CT scan
time requirements. Moreover, although the synthesis technique and in vivo scans were
demonstrated using erbium as contrast material, it can easily be substituted by any other
lanthanide given that the same number of moles is used in the synthesis as the different
lanthanide have very similar chemistry.
While the agent that was synthesized in Chapter 2 provided high vascular contrast for
periods that meet micro-CT scan time requirements, the scanned subjects frequently
expired within two days of intravenous injections. Hence, an alternative nanoparticle
design was explored in Chapter 3, where in lieu of using an amphiphilic polymer to
encapsulate nanoparticles, PEG was grafted directly onto the lanthanide nanoparticle
surface, which was NaGdF4 in this study, resulting in particles with smaller overall
diameters. The new formulation still suspends at least 100 mg/mL of lanthanides, and
permitted survival for at least 5 days. Imaging and quantitative analysis of gadolinium in
tissues showed the presence of contrast agent in clearance organs including the liver and
spleen and very low amounts in other organs. In vitro cell culture experiments,
subcutaneous injections, and analysis of mouse body weight suggested that the agents
exhibited low toxicity. Histological analysis of tissues 5 days after injection of the contrast
agent showed cytotoxicity in the spleen, but no abnormalities were observed in the liver,
lungs, kidneys, and bladder. CT contrast enhancements of at least 245 HU were observed
in the blood pool, which however, slowly started decreasing in as little as 10 minutes after
injections. Hence, we observed a tradeoff between circulation time and animal viability for
the formulations presented in this Chapter and in Chapter 2, where the longer the
circulation time, the lower the chances of animal viability. Since the ultimate goal of this
thesis was to demonstrate the feasibility of in vivo DE CT of the vasculature, the
formulation from Chapter 2, which provided longer circulation times, was selected for
further imaging studies, to maintain as much contrast as possible in the blood pool of the
scanned subjects.
In Chapter 4, I demonstrated the feasibility of in vivo DE micro-CT using a gadolinium
contrast agent that was synthesized as presented in Chapter 2. A tube potential of 90 kVp
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was selected, and the spectral separation between the low-energy and high-energy spectra
was optimized using SPEKTR 3.0 simulations. This protocol was implemented by the
interleaved acquisition of DE CT images, through cylindrical shell filters composed of
copper and a solution of gadolinium in water (obtaining high- and low-energy images,
respectively), and an automated filter exchange mechanism. However, since the filters and
mouse bed had to be set up outside the micro-CT gantry, the delay between injection time
and scan time resulted in lower vascular contrast than anticipated. Sub-voxel displacements
were also observed between mouse positions in the low-energy and high-energy images.
Nonetheless, fiducial marker beads enabled the co-registration of DE images, for volume
decomposition by the matrix factorization algorithm. The results show that the in vivo
DE CT technique that can produce quantitative images of decomposed soft tissue, bone
and gadolinium-enhanced vessels volumes that can identify major vessels from
surrounding bone, which can be used with any pre-clinical, gantry-based micro-CT
scanner. Vessels at least 0.25 mm in diameter can be distinguished from surrounding bone,
which can be improved by reducing set up time, possibly increasing in vivo vascular
contrast. While further studies are required to optimize subject setup and to investigate the
ability of this technique to overcome partial volume effects, our results demonstrate the
feasibility of in vivo DE CT of the vasculature.

5.2

Future Directions

This thesis presented methods to synthesize two versions of long-circulating lanthanidebased nanoparticle contrast agents that can be used for micro-CT imaging of the
vasculature, characterized these agents in vitro and in vivo, and demonstrated the feasibility
of DE micro-CT imaging of the mouse vasculature in vivo. The results that were obtained
from the characterization of the agents in this thesis indicate opportunities that can further
improve the viability of the injected animals, and prospective applications of the in vivo
DE micro-CT technique that is presented.

5.2.1

Non-rigid Nanoparticles as Contrast Agents

In Chapter 3, one version of the synthesized contrast agents (PPEG2000-GdNP, which
demonstrated transient hydrodynamic diameters as measured by dynamic light scattering
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in vitro) was found to accumulate at a lower concentration in the liver and the spleen than
the colloidally stable version (PPEG5000-PPEG1000-GdNP). It is suspected that the size
transience of PPEG2000-GdNP – demonstrated within minutes of incubation with saline and
a mouse serum mimic – promoted mobility and reduced accumulation in RES organs. This
was previously demonstrated by other researchers that studied nanogels of varying rigidity,
reporting greater particle mobility and lower accumulation in clearance organs with less
rigid nanogels than rigid nanogels.5,

6

Hence, nanoparticles that are less rigid than

PPEG2000-GdNP, but have the same physical properties (i.e. PEG-coated with a
hydrodynamic diameter of close to 50 nm) can be studied.
Most biocompatible polymers exhibit gradual degradation in vivo, including PEG.
However, polymers can be developed such that they degrade when exposed to specific
stimuli, such as light, change in pH, or mechanical force. Such polymers are either
degradable stimuli responsive polymers, which require multiple stimuli events to
completely degrade,7 or self-immolative polymers (SIPs), which can depolymerize of the
from end-to-end after cleavage of a stimuli-responsive end cap The main advantage of
using SIPs are the tunability of their end-caps. Specifically, polyglyoxylates are a
promising class of SIPs that have been synthesized in the form of poly(methyl glyoxylate)
(PMeG)8 and poly(ethyl glyoxylate) (PEtG),9 which the Gillies group specializes in. PEtG
can be coupled to PEG to create an amphiphilic diblock copolymer (PEG-PEtG) that can
be used to encapsulate the lanthanide nanoparticles that were synthesized in this thesis
within polymer assemblies. Lanthanide nanoparticle assemblies encapsulated within PEGPEtG will likely demonstrate similar circulation times as the assemblies that were studied
in Chapter 2, except that they have the potential to accumulate at lower concentrations in
RES organs due to their more rapid degradation.

5.2.2

Imaging Abnormal Tissues via Vascular Permeability

Vascular permeability is a property that accompanies tissue abnormalities, such as tumors
and soft tissue injury.10, 11 Nanoparticles are known to accumulate in tumors, and have been
used to opacify tumor tissues in micro-CT images,12 as well as in DE micro-CT scans.13.
Similarly, some previous evidence to show that the damage induced by ischaemiareperfusion injury alters vascular permeability in the heart,11 where nanoparticle
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accumulation has been demonstrated in vivo.14 The contrast agents presented in Chapters
2 and 3 can be used to image tumors and ischaemic insult, both using single energy microCT and in DE micro-CT. Since extravascular micro-CT relies on contrast agent localization
in the tissue of interest, lower administration volumes are required, with even lower
concentration requirements when performing DE micro-CT scans as presented in Chapter
4. For instance, the imaging technique presented can be used to observe the response of
tumors or ischaemic tissue in the heart to therapeutic drugs.

5.2.3

Evaluating In Vivo Vessel Density

One of the main advantages of DE CT is its ability to overcome the partial volume effect,
which would be especially useful to quantify microvessel density. For instance, an
optimized version of the DE CT technique that is presented in Chapter 4 can be used to
obtain quantitative images of gadolinium-enhanced vessels, which would represent blood
vessel density. With an optimized in vivo longitudinal DE CT technique, the response of
injured muscles to vascular endothelial growth factors can be quantified.

5.3

Summary

In conclusion, this thesis has described the development of a lanthanide-based nanoparticle
contrast agent that can be used for in vivo micro-CT imaging of the mouse vasculature. The
contrast agents presented can concentrate a high loading of 100 mg/mL of gadolinium for
intravenous injections of mice. They introduced CT contrast enhancements of at least
245 HU for at least 30 minutes, and for as long as one hour, which well exceeds in vivo
micro-CT scan time requirements. Moreover, although the synthesis techniques and in vivo
scans were demonstrated using gadolinium and erbium as contrast materials, they can
easily be substituted by any other lanthanide. An in vivo DE CT technique which can be
used with any pre-clinical, gantry-based micro-CT scanner was also presented. The in vivo
technique produced quantitative images of decomposed soft tissue, bone and gadoliniumenhanced vessels volumes, which was capable of distinguishing major vessels from
surrounding bone. The long-circulating lanthanide contrast agents that were developed in
this thesis, when used in combination with the DE CT technique presented, have the
potential to become a powerful tool for preclinical research of the microvasculature.
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Appendix A: Supporting Information for Chapter 2
General Materials
Erbium chloride, PEG monomethyl ether (mPEG, Mn = 2000, 5000), PEG-poly(propylene
glycol)-PEG (poloxamers) (PEG76-PPG22-PEG76 for Mn = 8400, PEG137-PPG34-PEG137 for
Mn = 14600), ε-caprolactone (ε-CL), methanesulfonic acid, 1,5,7-triazabicyclo[4.4.0]dec5-ene (TBD), diisopropylethylamine (DIPEA), benzoic acid, 1-pyrenemethanol, and
450 nm cellulose acetate membrane syringe filters were purchased from Millipore Sigma
(Oakville, ON). L-lactide, ammonium fluoride, oleic acid, and 1-octadecene were
purchased from Alfa Aesar (Ward Hill, MA). Sodium hydroxide, calcium hydride,
methanol, hexane, tetrahydrofuran (THF), hydrochloric acid, nitric acid, and SEC grade
N,N-dimethylformamide (DMF) were purchased from Caledon Laboratories (Georgetown,
ON). Ethanol was purchased from Commercial Alcohols (Tiverton, ON). Deuterated
chloroform (CDCl3) was purchased from Cambridge Isotope Laboratories (Andover, MA).
Dry toluene was obtained from a solvent purification system, and ε-CL was distilled from
calcium hydride, both stored over molecular sieves. PEG was dried by heating at 110 °C
for 1 hour under high vacuum immediately before use. An erbium standard with a
concentration of 10,000 µg/mL was purchased from Delta Scientific Laboratory Products
Ltd. (Mississauga, ON). Spectra/Por 6 dialysis tubing (50 kDa MWCO) was obtained from
Spectrum Laboratories (Rancho Dominguez, CA). Normal saline (0.9 % NaCl) was
purchased from Cardinal Health (Mississauga, ON). Mouse Primary Antibody Isotype
Control, which is a mouse serum mimic, fetal bovine serum (FBS), Glutamax (100X)
solution Penstrep (100X), and Dulbecco’s modified Eagle’s medium were obtained from
Invitrogen Corporation (Camarillo, CA). C57BL/6 male mice (25–30 g) were purchased
from Jackson Laboratories (Bar Harbor, ME), isoflurane from Baxter Corporation
(Mississauga, ON) and diphenhydramine from Sandoz (Boucherville, QC).

General methods
The nanoparticle hydrodynamic diameters were measured by dynamic light scattering
(DLS) using a Zetasizer Nano ZS instrument (Malvern Instruments Ltd, Malvern UK) at

114

room temperature (25°C) in a quartz cuvette (1 mg/mL). Transmission electron microscopy
(TEM) was performed using a Philips CM10 (Philips, Amsterdam) using an acceleration
voltage of 80 kV. A drop from a suspension of the samples in water (1 mg/mL) was
deposited onto a copper grid and air-dried overnight. Samples were centrifuged in 50 mL
tubes using a VWR Clinical 200 centrifuge with a 28° fixed-angle rotor. 1H (400 MHz)
nuclear magnetic resonance (NMR) spectra were obtained using a Varian Inova 400
spectrometer (Mississauga, ON). Chemical shifts are reported in parts per million (ppm)
and were calibrated against residual solvent signals of chloroform (CDCl3, δ 7.27). Size
exclusion chromatography (SEC) data were obtained using a Waters 515 pump (Waters
Limited, Mississauga, ON) equipped with an Optilab rEX detector (Wyatt Technologies,
Santa Barbara, CA) and two PLgel 5 μm mixed-D (300 mm × 7.5 mm) columns connected
in series (Varian, Canada). Samples (5 mg/mL) dissolved in the eluent, composed of 10
mM LiBr and 1% (v/v) NEt3 in DMF at 85 °C were injected (100 μL) at a flow rate of 1
mL/min and calibrated against polystyrene standards. Molecular weights are reported in
g/mol. The erbium content of samples that were digested and preserved with aqua regia
(2%) were measured by inductively coupled plasma mass spectrometry (ICP-MS) using
the Agilent 1260 Infinity HPLC connected directly to a new Agilent 7700 Series ICP-MS
(Santa Clara, CA).

Synthesis of NaErF4 nanoparticles (ErNP)
ErNP were synthesized based on a previously reported method with modifications
(Figure A.1) 1, 2. Erbium chloride (1660 mg, 6.0 mmol, 1.0 equiv), oleic acid (90 mL), and
1-octadecene (90 mL) were magnetically stirred and subjected to high vacuum. The
resulting mixture was heated to 120 °C for 1 hour, then cooled to 50 °C under argon.
Ammonium fluoride (900 mg, 24.5 mmol, 4.0 equiv) and sodium hydroxide (600 mg,
15 mmol, 2.5 equiv) were dissolved in 50 mL of methanol and added dropwise to the
cooled mixture. The solution was kept under the same conditions for 30 minutes. It was
then heated to 65 °C under vacuum for 30 minutes to evaporate methanol, and then to 100
°C for another 30 minutes to evaporate water. High vacuum was removed and the mixture
was placed under an argon atmosphere. The mixture was heated to 300 °C for 2 hours and
cooled to room temperature for purification.
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Figure A.1 Synthesis of oleate-coated NaErF4 nanoparticles.
To precipitate the nanoparticles, ethanol was added to the resulting solution at a 5:1 volume
ratio and centrifuged at 6000 rpm for 30 minutes. The supernatant was decanted, the
nanoparticles were redispersed in THF, and the solution was centrifuged again. Sedimented
nanoparticles were dried under vacuum overnight and stored at room temperature. A
1 mg/mL sample of the nanoparticles was prepared in THF for characterization by DLS
and TEM.

Figure A.2 Intensity distributions of ErNP in THF measured by DLS.
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Synthesis of PEG-PCL diblock copolymers
PEG-PCL diblock copolymers (of varying molecular weights) were synthesized via ring
opening polymerization of ε-CL using mPEG as an initiator (Table A.1) following a
previously reported method with some modifications (Scheme A.1)3. mPEG (0.50 g) and
toluene (5 mL) and were added to a flame-dried round bottom flask. ε-CL and
methanesulfonic acid were then added in varying ratios to obtain different polymer chain
length targets. The solution was stirred for 5-6 hours at room temperature. DIPEA (32 mg,
0.25 mmol, 1.0 or 2.5 equiv) was added to quench the reaction. The solution was added to
hexane (250 mL) to precipitate the resulting diblock copolymer. The supernatant was
decanted and polymer precipitation was repeated twice. The polymer was dried under
vacuum overnight and refrigerated. 1H NMR spectroscopy and SEC were used to
characterize the diblock copolymers.

Table A.1. Experimental details of PEG-PCL diblock copolymers synthesis.
methanesulfonic
acid
Mw
m
n
V
n
m
n
equiv
equiv
equiv
(g/mol) (mg) (mmol)
(mL) (mmol)
(mg) (mmol)
ε-CL

mPEG

Sample name

PEG45-PCL20

2000

500

0.25

1.0

0.5

5.51

18.0

24

0.25

1.0

PEG45-PCL51

2000

500

0.25

1.0

1.0

9.02

36.1

13

0.25

1.0

PEG114-PCL51

5000

500

0.1

1.0

0.5

5.87

58.7

10

0.1

1.0

PEG114-PCL97

5000

500

0.1

1.0

1.0

7.22

72.2

5

0.1

1.0

Scheme A.1. Synthesis of PEG-PCL.
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Synthesis of PEG-PLA diblock copolymers
PEG-PLA diblock copolymers (of varying molecular weights) were synthesized via ring
opening polymerization of L-lactide using mPEG as an initiator (Table A.2) following a
previously reported method with some modifications (Scheme A.2) 4. mPEG and toluene
(5 mL) were added to a flame-dried round bottom flask. L-lactide and TBD were then added
in varying ratios to obtain different polymer chain lengths. The solution was stirred for 5
minutes at room temperature. Benzoic acid (30 mg, 0.25 mmol, 1.0 or 2.5 equiv) was added
to quench the reaction. After that, the solution was added to hexane (250 mL) to precipitate
the resulting diblock copolymers. The supernatant was decanted and polymer precipitation
was repeated twice. The polymer was dried under vacuum overnight and refrigerated. 1H
NMR spectroscopy and SEC were used to characterize the diblock copolymers.

Table A.2. Experimental details of PEG-PLA diblock copolymers synthesis.
mPEG
Sample name

methanesulfonic
acid

L-lactide

Mw
m
n
n
m
n
equiv m (g)
equiv
equiv
(g/mol) (mg) (mmol)
(mmol)
(mg) (mmol)

PEG45-PLA25

2000

500

0.25

1.0

0.50

4.51

18.0

24

0.25

1.0

PEG45-PLA52

2000

500

0.25

1.0

1.00

9.02

36.1

13

0.25

1.0

PEG114-PLA53

5000

500

0.1

1.0

0.65

5.87

58.7

10

0.1

1.0

PEG114-PLA122 5000

500

0.1

1.0

0.80

7.22

72.2

5

0.1

1.0

Scheme A2. Synthesis of PEG-PLA.
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Characterization of diblock copolymers
Data obtained from 1H NMR (Figures A.3-A.10) and SEC (Figures A.11-A.14) are
summarized in Table 1. Typical signals of PEG, PCL and PLA components were utilized
to calculate the molecular weights of diblock copolymers. The signal at 3.65 ppm (–
CH2CH2–) was assigned to the PEG block. Signals at 1.34-1.43, 1.58-1.67, 2.26-2.33 and
4.02-4.08 ppm were assigned to different methylene protons (–CH2–) of PCL blocks. The
molar ratio of polymerized CL to PEG was determined by integrating peak intensities of
methylene protons from the PEG block at 3.60-3.65 ppm and PCL block at 4.02-4.08 ppm.
This was repeated for PLA where signals at 1.21-1.22, 1.56-1.61 and 5.14-5.19 ppm were
assigned to the PLA block and peak integrations from the PLA block at 5.14-5.19 ppm
were used to calculate the molar ratio of polymerized LA to PEG. The peaks around 2.36
and 7.15-7.30 corresponds to residual toluene (as do the peaks around the chloroform-d
peak). The NMR and SEC results for all the synthesized polymers are as follows, where
Mna is the number average molecular weight from NMR, Mnb is the SEC-measured number
average molecular weight and the dispersity from SEC is Đ.
PEG45-PCL20: 1H NMR (CDCl3, 400 MHz): δ 4.06 (t, J = 7.0 Hz, 40H), 3.65 (s, 182H),
2.31 (t, J = 7.7 Hz, 41H), 1.64 (tt, J = 6.5, 13.0 Hz, 80H), 1.34 – 1.41 (m, 41H). Mna = 4300
g/mol. SEC: Mnb = 5600 g/mol, Mw = 6200 g/mol, Đ = 1.1.
PEG45-PCL51: 1H NMR (CDCl3, 400 MHz): δ 4.06 (t, J = 7.0 Hz, 101H), 3.65 (s, 182H),
2.82 (s, 31H), 2.31 (t, J = 7.9 Hz, 103H), 1.64 (tt, J = 6.5, 13.2 Hz, 214H), 1.34 – 1.40 (m,
106H). Mna = 7800 g/mol. SEC: Mnb = 6300 g/mol, Mw = 8800 g/mol, Đ = 1.4.
PEG114-PCL51: 1H NMR (CDCl3, 400 MHz): δ 4.06 (t, J = 6.9 Hz, 101H), 3.65 (s, 455H),
2.40 (s, 32H), 2.31 (t, J = 7.9 Hz, 128H), 1.64 (tt, J = 6.6, 14.5 Hz, 258H), 1.35-1.40 (m,
133H). Mna = 10900 g/mol. SEC: Mnb = 9500 g/mol, Mw = 10500 g/mol, Đ = 1.1.
PEG114-PCL97: 1H NMR (CDCl3, 400 MHz): δ 4.06 (t, J = 7.1 Hz, 195H), 3.65 (s, 455H),
2.31 (t, J = 7.8 Hz, 247H), 1.66 (tt, J = 6.7, 14.2 Hz, 392H), 1.39 (tt, J = 7.5, 16.1 Hz,
199H). Mna = 16100 g/mol. SEC: Mnb = 10300 g/mol, Mw = 13400 g/mol, Đ = 1.3.
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PEG45-PLA25: 1H NMR (CDCl3, 400 MHz): δ 5.17 (q, J = 8.1 Hz, 25H), 3.65 (s, 182H),
1.52 – 1.59 (m, 81H). Mna = 4300 g/mol. SEC: Mnb = 5200 g/mol, Mw = 6200 g/mol, Đ =
1.2.
PEG45-PLA52: 1H NMR (CDCl3, 400 MHz): δ 5.19 (q, J = 8.3 Hz, 52H), 3.68 (s, 182H),
1.57 – 1.63 (x, 167H). Mna = 6700 g/mol. SEC: Mnb = 9600 g/mol, Mw = 10600 g/mol, Đ
= 1.1.
PEG114-PLA53: 1H NMR (CDCl3, 400 MHz): δ 5.18 (q, J = 8.1 Hz, 53H), 3.65 (s, 455H),
1.53 – 1.60 (m, 188H). Mna = 9800 g/mol. SEC: Mnb = 10500 g/mol, Mw = 12700 g/mol,
Đ = 1.3.
PEG114-PLA122: 1H NMR (CDCl3, 400 MHz): δ 5.18 (q, J = 8.2 Hz, 122H), 3.65 (s, 455H),
1.53 – 1.60 (m, 417H). Mna = 16000 g/mol. SEC: Mnb = 13500 g/mol, Mw = 18900 g/mol,
Đ = 1.4.

Figure A3. 1H NMR spectrum of PEG45-PCL20 (CDCl3, 400 MHz).
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Figure A4. 1H NMR spectrum of PEG45-PCL51 (CDCl3, 400 MHz).

Figure A5. 1H NMR spectrum of PEG114-PCL51 (CDCl3, 400 MHz).

Figure A6. 1H NMR spectrum of PEG114-PCL97 (CDCl3, 400 MHz).
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Figure A7. 1H NMR spectrum of PEG45-PLA25 (CDCl3, 400 MHz). Note that the polymer
contains trace residual toluene.

Figure A8. 1H NMR spectrum of PEG45-PLA52 (CDCl3, 400 MHz). Note that the polymer
contains trace residual toluene.

Figure A9. 1H NMR spectrum of PEG114-PLA53 (CDCl3, 400 MHz). Note that the polymer
contains trace residual toluene.
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Figure A.10. 1H NMR spectrum of PEG114-PLA122 (CDCl3, 400 MHz). Note that the
polymer contains trace residual toluene.

Figure A.11. SEC traces of the mPEG45 (Mn = 3900 g/mol, Đ = 1.1) initiator, PEG45-PCL20
(Mn = 5600 g/mol, Đ = 1.1) and PEG45-PCL51 (Mn = 6300 g/mol, Đ = 1.4).
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Figure A.12. SEC of the PEG114 (Mn = 7100 g/mol, Đ = 1.1) initiator, PEG114-PCL51 (Mn
= 9500 g/mol, Đ = 1.1) and PEG114-PCL97 (Mn = 10300 g/mol, Đ = 1.3).

Figure A.13. SEC of the PEG45 (Mn = 3900 g/mol, Đ = 1.1) initiator, PEG45-PLA25 (Mn =
5200 g/mol, Đ = 1.2) and PEG45-PLA52 (Mn = 9600 g/mol, Đ = 1.1).
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Figure A.14. SEC of the PEG114 (Mn = 7100 g/mol, Đ = 1.1) initiator, PEG114-PLA53 (Mn
= 10500 g/mol, Đ = 1.3) and PEG114-PLA122 (Mn = 13500 g/mol, Đ = 1.4).

Self-assembly of polymeric nanoparticles (without ErNP)
via nanoprecipitation
In 0.2 mL of THF, 8 mg of copolymer were dissolved. The solution was then added
dropwise to 1.8 mL of deionized water under magnetic stirring. After 1 hour, stirring was
stopped and the solution was left uncapped for 12 hours to allow for organic solvent
evaporation. The solutions were dialyzed against 100 mL of deionized water for 2 days
with 5 solvent changes. A 450 nm syringe filter was used to separate large aggregates and
the samples were characterized by DLS (Figure A.15) and TEM (Figure A.16).
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Figure A.15. Volume diameter distributions of polymeric nanoparticles prepared using a)
PEG76-PPG22-PEG76, b) PEG137-PPG34-PEG137, c) PEG45-PCL20, d) PEG45-PCL51, e)
PEG114-PCL51, f) PEG114-PCL97, g) PEG45-PLA25, h) PEG45-PLA52, i) PEG114-PLA53, and
j) PEG114-PLA122, as measured by DLS.

Figure A.16. TEM images of assemblies prepared from a) PEG76-PPG22-PEG76, b)
PEG137-PPG34-PEG137, c) PEG45-PCL20, d) PEG45-PCL51, e) PEG114-PCL51, f) PEG114PCL97, g) PEG45-PLA25, h) PEG45-PLA52, i) PEG114-PLA53, and j) PEG114-PLA122.
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Figure A.17. The colloidal stability of the PEG-PPG-PEG-encapsulated ErNP. The
PEG76-PPG22-PEG76 assemblies, which had a Z-average hydrodynamic diameter of 174 ±
4 nm redispersed in saline at a diameter of 294 ± 34 nm, while the PEG137-PPG34-PEG137
assemblies, which had an initial diameter of 176 ± 6 nm in size redispersed at 212 ± 2 nm.
Although a larger increase in size was observed initially with the PEG76-PPG22-PEG76
assemblies, the hydrodynamic diameter of both samples fluctuated around 200 nm for up
to 60 minutes.

Figure A.18. The colloidal stability of the PEG-PCL-encapsulated ErNP. All assemblies
redispersed in saline as micron-sized particles.
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Figure A.19. The colloidal stability of the PEG-PLA-encapsulated ErNP. The PEG45PLA52 and PEG114-PCL122 encapsulations redispersed saline at larger diameters. The
PEG45-PLA25 and PEG114-PCL53 encapsulations maintained their hydrodynamic diameters
after dispersion in saline and remained stable for 60 minutes.

Figure A20. DLS volume distribution of diameters for the mouse serum mimic alone,
without any assemblies. The instrument reported that the data quality was not good due to
the count rate being too low. This suggested that the proteins in the serum mimic would
have minimal interference in the analysis of the assemblies (Figure A21).
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Figure A21.

DLS

volume distributions of

diameters

for

the polymer-

encapsulated ErNP in a mouse serum mimic. The PEG114-PLA53:ErNP ratios are a) 4:1, b)
2:1, c) 1:1 and d) 0.5:1.

Critical aggregation concentration measurements
The critical aggregation concentrations (CAC) of the 1:1 and 0.5:1 PEG114-PLA53:ErNP
assemblies were determined using pyrene as the fluorescent probe.5 The assemblies were
prepared as described in the manuscript with and without ErNP. Each suspension was
lyophilized and redispersed in 0.1 M, pH 7.4 phosphate buffer at a polymer concentration
of 1 mg/mL. The resulting solution was diluted to prepare concentrations from 0.001 1 mg/mL of polymer. Each of these solutions (1 mL) was added to a vial containing
0.025 mg of pyrene, and was incubated for 20 h at 37 °C. The fluorescence emission
spectrum (350-700 nm) of each solution was obtained using an excitation wavelength of
334 nm. The emission intensities of the first vibronic band (I1) of pyrene at 371 nm and its
third vibronic band (I3) at 382 nm were obtained and the I1/I3 ratio was plotted against
log10[concentration (mg/L)] to give a sigmoidal curve. The CAC was determined to be the
point of intersection between the horizontal linear segment at low concentration and the
linear region of negative slope.
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Figure A22. Ratio of the emission intensities (I1/I3) versus Log10 of the polymer
concentration in mg/mL for the PEG114-PLA53 only assembly. The CAC was determined
to be at 0.026 mg/mL.

Figure A23. Ratio of the emission intensities (I1/I3) versus Log10 of the polymer
concentration in mg/mL for the 1:1 PEG114-PLA53:ErNP ratio. The CAC was determined
to be at 0.096 mg/mL.
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Figure A24. Ratio of the emission intensities (I1/I3) versus Log10 of the polymer
concentration in mg/mL for the 0.5:1 PEG114-PLA53:ErNP ratio. The CAC was determined
to be at 0.117 mg/mL.

Figure A25. (a) Micro-CT image (at 80 kVp) of calibration standards containing known
concentrations of erbium chloride, which were used to determine the erbium content of the
0.5:1 and 1:1 PEG114-PCL53:ErNP formulations. (b) Measured CT number vs. known
erbium concentration.
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Figure A26. Micro-CT image (at 80 kVp) of the erbium calibration standards and the
concentrated 0.5:1 and 1:1 PEG114-PCL53:ErNP formulations. The CT numbers of the
concentrated solutions verified the suspension of over 100 mg/mL of erbium in each of the
formulations.

Cell viability assay
C2C12 mouse myoblast cells were seeded in a Nunclon 96-well U-bottom transparent
polystyrol plate to obtain approximately 10,000 cells/well in 100 μL of Dulbecco’s
modified Eagle’s medium containing serum, glutamax, and antibiotics. The cells were
allowed to adhere to the plate in a 5% CO2 incubator at 37 °C for 24 h. The growth medium
was then aspirated and replaced with either solutions of sodium dodecyl sulfate (SDS) in
the cell culture medium at concentrations of 0.2, 0.15, 0.10, or 0.05 mg/mL, which were
used as positive controls, serial dilutions of the contrast agent, or fresh medium. The cells
were then incubated at 37°C (5% CO2) for 24 h. The medium was again aspirated and
replaced with 110 μL of fresh medium containing 0.5 mg/mL (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) (MTT). After 4 h of incubation (37°C, 5% CO2), the
MTT solution was carefully aspirated and the purple crystals were dissolved by addition
of 50 μL of spectroscopic grade dimethyl sulfoxide (DMSO). After shaking (1 s, 2 mm
amp, 654 rpm), the absorbance of the wells at 540 nm was read using an M1000-Pro plate
reader (Tecan). The absorbance of wells prepared in the same way but without cells was
subtracted as a background and the cell viability was calculated relative to wells containing
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cells that were exposed only to the culture medium. Cell viability was detected for cells
exposed to only to the lowest concentrations of SDS, confirming the sensitivity of the
assay.

Figure A27. In vitro toxicity as determined by the MTT assay of the contrast agent
formulated with a) 1:1 and b) 0.5:1 polymer to erbium mass ratios.

In Vivo reaction test in subcutaneous tissue
C57BL/6 mice (25-30 g) were injected with 0.2 mL of the 1:1 (n = 2) and 0.5:1 (n = 2)
mass ratio formulations of the contrast agent. These animals were scanned before contrast
agent administration, and 2 minutes and two weeks post-injection. The animals were
scanned using general micro-CT imaging and analysis methods as described in the
manuscript. Representative images of a mouse from each group are shown in Figure A29.
Both formulations of the contrast agent localized near the injection site for up to two weeks
after injection. The animals were sacrificed at the two week timepoint for subcutaneous
and dermal tissue gross examination (Figure A30). Both the dermal and subcutaneous
tissue appeared normal.
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Figure A28. Representative sagittal micro-CT images showing mice that received contrast
agent formulated at a) 1:1 and b) 0.5:1 PEG114-PLA53:ErNP mass ratios subcutaneously.
The location of the injection site (subcutaneous tissue) is outlined in the precontrast image.
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Figure A29. Dermal (left) and subcutaneous (right) tissue of mice that received contrast
agent formulated at a) 1:1 and b) 0.5:1 PEG114-PLA53:ErNP mass ratios. The arrows
indicate the injection site and contrast agent localization.
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Appendix B: Supporting Information for Chapter 3
General Materials
Gadolinium chloride hexahydrate, PEG monomethyl ether (mPEG, Mn = 1000, 2000,
5000), and 450 nm cellulose acetate membrane syringe filters were purchased from
Millipore Sigma (Oakville, ON). Sterile disposable filter units 450 nm pore size were
purchased from ThermoFisher Scientific (Ottawa, ON). Ammonium fluoride, oleic acid,
1-octadecene, and phosphoryl trichloride were purchased from Alfa Aesar (Ward Hill,
MA). Sodium hydroxide, hexane, tetrahydrofuran (THF), hydrochloric acid, and nitric acid
were purchased from Caledon Laboratories (Georgetown, ON). Ethanol was purchased
from Commercial Alcohols (Tiverton, ON). Dry toluene was obtained from a solvent
purification system and was stored over molecular sieves. PEG was dried by heating at 110
°C for 1 hour under high vacuum immediately before use. A gadolinium standard with a
concentration of 10,000 µg/mL was purchased from Delta Scientific Laboratory Products
Ltd. (Mississauga, ON). Spectra/Por 6 dialysis tubing (50 kDa MWCO) was obtained from
Spectrum Laboratories (Rancho Dominguez, CA). Normal saline (0.9 % NaCl) was
purchased from Cardinal Health (Mississauga, ON). Mouse Primary Antibody Isotype
Control, which is a mouse serum mimic, fetal bovine serum (FBS), Glutamax (100X)
solution Penstrep (100X), and Dulbecco’s modified Eagle’s medium were obtained from
Invitrogen Corporation (Camarillo, CA). C57BL/6 male mice (25–30 g) were purchased
from Jackson Laboratories (Bar Harbor, ME), and isoflurane from Baxter Corporation
(Mississauga, ON).

General characterization methods
The nanoparticle hydrodynamic diameters were measured by dynamic light scattering
(DLS) using a Zetasizer Nano ZS instrument (Malvern Instruments Ltd, Malvern UK) at
room temperature (37°C) in a quartz cuvette (1 mg/mL). Transmission electron microscopy
(TEM) was performed using a Philips CM10 (Philips, Amsterdam) using an acceleration
voltage of 80 kV. A drop from a suspension of the samples in cyclohexane or water
(1 mg/mL) was deposited onto a copper grid and air-dried overnight. Samples were
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centrifuged in 50 mL tubes using a VWR Clinical 200 centrifuge with a 28° fixed-angle
rotor. The gadolinium content of samples that were digested and preserved with aqua regia1
(2%) were measured by inductively coupled plasma mass spectrometry (ICP-MS) using
the Agilent 1260 Infinity HPLC connected directly to a new Agilent 7700 Series ICP-MS
(Santa Clara, CA).

Synthesis of gadolinium nanoparticles (GdNP)
Specifically, the GdNP in this study are NaGdF4 nanocrystals and were synthesized based
on a previously reported method with some modifications.2,

3

Gadolinium chloride

hexahydrate (2230 mg, 6.0 mmol, 1.0 equiv), oleic acid (90 mL), and 1-octadecene (90
mL) were magnetically stirred and subjected to high vacuum. The resulting mixture was
heated to 120°C for 1 hour, then cooled to 50 °C under argon. Ammonium fluoride
(900 mg, 24.5 mmol, 4.0 equiv) and sodium hydroxide (600 mg, 15 mmol, 2.5 equiv) were
dissolved in 50 mL of methanol and added dropwise to the cooled mixture. The solution
was kept under the same conditions for 30 minutes. It was then heated to 65 °C under
vacuum for 30 minutes to evaporate methanol, and then to 100 °C for another 30 minutes
to evaporate water. High vacuum was removed, and the mixture was placed under an argon
atmosphere. The mixture was heated to 300 °C for 2 hours and cooled to room temperature
for purification.
To precipitate the nanoparticles, ethanol was added to the resulting solution at a 5:1 volume
ratio and centrifuged at 6000 rpm for 30 minutes. The supernatant was decanted, the
nanoparticles were redispersed in THF, and the solution was centrifuged again. Sedimented
nanoparticles were dried under vacuum overnight and stored at room temperature. A
1 mg/mL sample of the nanoparticles was prepared in cyclohexane for characterization by
DLS and TEM.

Purification of PEG-coated nanoparticles
The solution containing PEG-coated GdNP were dialyzed against 4 L of milliQ water over
24 hours, with 5 dialysate changes. The resulting solution was filtered via sterile vacuum
filtration (450 nm pore size), and then lyophilized.
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Linear regression
concentration

of

CT

contrast

and

gadolinium

The relationship between CT contrast and gadolinium concentration was first confirmed
by micro-CT. Gadolinium chloride was diluted in saline at gadolinium concentrations of
5, 10, 15 and 100 mg/mL, which acted as calibration standards. The dried contrast agent
was dissolved in saline to contain 100 mg/mL of gadolinium; the mass of dried contrast
agent required to obtain 100 mg/mL of gadolinium was determined from ICP-MS data.
The linear regression between CT contrast (in HU) and gadolinium concentration was then
used to calculate the gadolinium content of the contrast agent.

Cell viability assay
C2C12 mouse myoblast cells were seeded in a Nunclon 96-well U-bottom transparent
polystyrol plate to obtain approximately 10,000 cells/well in 100 μL of Dulbecco’s
modified Eagle’s medium containing serum, glutamax, and antibiotics. The cells were
allowed to adhere to the plate in a 5% CO2 incubator at 37 °C for 24 h. The growth medium
was then aspirated and replaced with either solutions of sodium dodecyl sulfate (SDS) in
the cell culture medium at concentrations of 0.2, 0.15, 0.10, or 0.05 mg/mL, which were
used as positive controls, serial dilutions of the contrast agent, or fresh medium. The cells
were then incubated at 37°C (5% CO2) for 24 h. The medium was again aspirated and
replaced with 110 μL of fresh medium containing 0.5 mg/mL (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) (MTT). After 4 h of incubation (37°C, 5% CO2), the
MTT solution was carefully aspirated and the purple crystals were dissolved by addition
of 50 μL of spectroscopic grade dimethyl sulfoxide (DMSO). After shaking (1 s, 2 mm
amp, 654 rpm), the absorbance of the wells at 540 nm was read using an M1000-Pro plate
reader (Tecan). The absorbance of wells prepared in the same way but without cells was
subtracted as a background and the cell viability was calculated relative to wells containing
cells that were exposed only to the culture medium. Cell viability was detected for cells
exposed to only to the lowest concentrations of SDS, confirming the sensitivity of the
assay.
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In vivo reaction test in subcutaneous tissue
C57BL/6 mice (25-32 g) were injected with 0.2 mL of saline (n=2), PPEG2000-GdNP (n=2),
or PPEG5000-PPEG1000-GdNP (n=2) subcutaneously, in the dorsal interscapular region.
These animals were scanned immediately after injection, and two weeks after. The animals
were scanned using general micro-CT imaging and analysis methods as described in the
manuscript. Representative images of a mouse from each group are shown in Figure B.3.
While both formulations of the contrast agent localized near the injection site for up to two
weeks, lower contrast was visualized at the two-week timepoint, suggesting clearance of
the contrast agent over time. after injection. The animals were sacrificed at the two-week
timepoint for subcutaneous, dermal tissue and clearance organs gross examination. All
tissues appeared normal.

Supplementary Results

Figure B.1. A) Micro-CT image (at 80 kVp) of calibration standards containing known
concentrations of gadolinium chloride, which were used to determine the gadolinium
content of the PPEG2000-GdNP and PPEG5000-PPEG1000-GdNP. B) Measured CT number
vs. known gadolinium concentration. The CT numbers of the concentrated solutions
verified the suspension of 100 mg/mL of gadolinium in each of the formulations. C) In
vitro cell viability as determined by MTT assay. No effect on viability was observed.
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Figure B.2. In vitro toxicity as determined by the MTT assay of the contrast agent.
PPEG2000-GdNP and PPEG5000-PPEG1000-GdNP did not cause toxicities to mouse myoblast
cells in vitro.

Figure B.3. Thick maximum intensity projections (5 cm) of mice injected subcutaneously.
Representative subjects were imaged immediately after injection with A) saline, B)
PPEG2000-GdNP, and C) PPEG5000-PPEG1000-GdNP. Images were also taken 2 weeks postinjections with D) PPEG2000-GdNP, and E) PPEG5000-PPEG1000-GdNP. The injection site
(i.e. dorsal interscapular region) is identified by the circle in A.
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Histological analysis of excised tissues
Hematoxylin stains the nucleus purple, while eosin counterstains the cytosol and
extracellular matrix pink.4 The heart, kidney and bladder tissues of injected mice
demonstrate no difference from control mouse tissues. Despite high gadolinium
concentrations in the liver, no difference in histological images were observed. The trace
amounts of gadolinium that were found in the lungs of PPEG5000-PPEG1000-GdNP-injected
mice did not result in notable differences. Contrasting histological staining is demonstrated
in the spleen, where control tissues have higher nuclear density than PPEG2000-GdNP- and
PPEG5000-PPEG1000-GdNP-injected mice. The spleen sections from the control mouse
demonstrates a deeper pink stain than the sections from injected mice, which appear purple.
Although representative sections are displayed in Figure B.4, similar images were
observed from different regions of the excised tissue.
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Figure B.4. Representative histology images for control and injected mice taken from
tissues after 5 days of injection. The liver, lung, heart, kidney, and bladder tissues appear
normal, while spleen tissue of the injected mice appear more purple than the staining
observed in the control mouse, which appears pink.
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Appendix C: Supporting Information for Chapter 4
Matrix Factorization
The implementation of dual-energy computed tomography (DE CT) decompositions in
Chapter 4 has been described in greater detail by Granton et al.1 The decomposition
algorithm relies on the solution of the following equations.
𝜇𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒,𝐻𝐸 𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝜇𝑏𝑜𝑛𝑒,𝐻𝐸 𝑓𝑏𝑜𝑛𝑒 + 𝜇𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚,𝐻𝐸 𝑓𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚 = 𝜇𝐻𝐸

(1)

𝜇𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒,𝐿𝐸 𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝜇𝑏𝑜𝑛𝑒,𝐿𝐸 𝑓𝑏𝑜𝑛𝑒 + 𝜇𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚,𝐿𝐸 𝑓𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚 = 𝜇𝐿𝐸

(2)

𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝑓bone + 𝑓𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚 = 1

(3)

In these equations, the known values are 𝜇𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 , 𝜇𝑏𝑜𝑛𝑒 , and 𝜇𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚 , which are
linear attenuation coefficients measured in each volume element (voxel) of soft tissue,
bone, and gadolinium, corresponding to the energy spectra indicated in the subscript (i.e.
HE for high-energy and LE for low-energy), and 𝜇𝐻𝐸 and 𝜇𝐿𝐸 , which are linear attenuation
coefficients in the high-energy and low-energy image, respectively. The algorithm solves
for 𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 , 𝑓𝑏𝑜𝑛𝑒 , and 𝑓𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚 , which represent the volume fractions or the
contribution of each material to the composition of a given voxel.
The linear attenuation coefficients are used interchangeably with the CT numbers that were
measured from acquired CT images due to the linear relationship between the two. Hence,
𝜇𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒,𝐻𝐸 , 𝜇𝑏𝑜𝑛𝑒,𝐻𝐸 , and 𝜇𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚,𝐻𝐸 were manually measured from calibrators,
which were mouse-specific CT numbers from the bladder, femoral cortical bone, and
abdominal aorta in the high-energy image, and likewise for low-energy CT numbers. The
algorithm automatically extracts a three-dimensional 𝜇𝐻𝐸 and 𝜇𝐿𝐸 from the input
low-energy and high-energy images. To calculate 𝑓𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒 , 𝑓𝑏𝑜𝑛𝑒 , and 𝑓𝑔𝑎𝑑𝑜𝑙𝑖𝑛𝑖𝑢𝑚 , the
total for each voxel is restricted to 1 (i.e. 100% composition).
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CT Attenuations Used in the Decomposition Algorithm
Table C.1. Mouse-specific attenuation values that were used in the DE decomposition
algorithm. CT attenuation was measured in (300 µm)3 volumes, averaged from three ROIs
within the same mouse tissue.

Mouse
number

1
2
3
4
5
6
7
8

Attenuation in the
low-energy image (HU)
Bladder

Femoral
Cortical
Bone

Abdominal
Aorta

57 ± 33
26 ± 22
52 ± 19
-11 ± 35
19 ± 25
80 ± 19
52 ± 22
3 ± 37

1300 ± 57
1145 ± 65
1250 ± 35
987 ± 46
1098 ± 46
1200 ± 22
1179 ± 56
1191 ± 36

185 ± 45
236 ± 36
225 ± 37
468 ± 43
128 ± 30
201 ± 33
127 ± 35
180 ± 25

Attenuation in the
high-energy image (HU)
Bladder

Femoral
Cortical
Bone

Abdominal
Aorta

25 ± 29
35 ± 33
-10 ± 20
5 ± 34
-42 ± 25
-20 ± 24
-30 ± 43
-54 ± 42

1203 ± 43
845 ± 56
1050 ± 55
1039 ± 39
827 ± 38
909 ± 46
954 ± 39
974 ± 55

160 ± 22
175 ± 35
170 ± 29
466 ± 53
104 ± 39
111 ± 34
101 ± 30
131 ± 29

Figure C.1. Gadolinium-enhanced vessels image on a) non-registered and b) co-registered
images. Substantial misclassification of bone and soft tissue in the gadolinium-enhanced
vessels image occurs predominantly near tissue borders.
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